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ABSTRACT OF THE DISSERTATION 
TRANSCRIPTION FACTOR 7-LIKE 2 (TCF7L2) GENE POLYMORPHISMS IN 
RELATION TO THE RISK OF TYPE 2 DIABETES IN THREE ETHNICITIES 
by 
Ling Xu 
Florida International University, 2018 
Miami, Florida 
Professor Fatma G. Huffman, Major Professor 
Type 2 Diabetes (T2D) disproportionally affects ethnic minorities in the United 
States. The development of T2D involves complex interaction between environmental 
factors and genetic predisposition. The genetic associations of six single nucleotide 
polymorphisms (SNPs) in TCF7L2 gene with the risk of T2D were evaluated in three 
high risk minority populations: Cuban Americans, Haitian Americans, and African 
Americans. For Cuban Americans, four SNPs (rs7901695, rs4506565, rs7903146 and 
rs11225537) were significantly associated with the risk of T2D after multivariable 
adjustment (p=0.018, p=0.016, p=0.014, and p=0.0008, respectively). Among controls, 
risk allele carriers of SNPs rs7901695, rs4506565 and rs7903146 had significantly higher 
fasting glucose level, compared to non-risk allele carriers. Additionally, a significant 
interaction between dietary fiber intake and SNP rs7903146 for the risk of T2D (p= 
0.044) was found in Cuban Americans. Similarly, for SNP rs7901695, significant 
interaction was also found for fiber intake (p=0.014) as well as glycemic load (p=0.040). 
Subgroup analysis revealed that significant associations were only found within higher 
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intake groups of dietary factors for both SNPs. For Haitian Americans, SNPs rs11196205 
(p=0.059) and rs7895340 (p=0.069) showed marginal significance for the risk of T2D. 
After stratification by gender, SNPs with marginal significance from the gender-
combined analysis became statistically significant with the same trend for the risk of T2D 
when analysis were done in males: rs11196205 (p=0.034) and rs7895340 (p=0.024). For 
African Americans, SNP rs7903146 (p=0.065) showed a marginal significance with the 
risk of T2D in gender-combined analysis and a statistical significance (p=0.013) in males. 
Two additional SNPs rs7901695 and rs4506565 were found to be significantly associated 
with the risk of T2D in males. Risk allele carriers of these two SNPs had significantly 
higher mean level of the fasting glucose level, compared to non-risk allele carriers in 
controls. T2D related quantitative trait analysis also demonstrated that in controls, 
compared to non-minor allele carriers of SNP rs12255372, minor allele carriers had 
significantly higher means of BMI, diastolic blood pressure, numbers of components of 
Metabolic Syndrome, significantly lower mean values of HDL-cholesterol and 
adiponectin. Taken together, our studies demonstrated ethno-specific genetic associations 
between TCF7L2 gene and the risk of T2D and related phenotypes. 
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CHAPTER I   INTRODUCTION 
Review of literature 
Diabetes is a complex, multi-factorial metabolic disorder characterized by 
hyperglycemia resulting from impaired pancreatic beta cell function, decreased action of 
insulin on target tissues, or both [1]. Most individuals with diabetes suffer serious 
complications of chronic hyperglycemia, involved in nephropathy, neuropathy, 
retinopathy, and accelerated development of cardiovascular disease [2]. Diabetes is 
currently the fastest-growing epidemic and a significant public health issue globally. The 
International Diabetes Federation estimated that 425 million people live with diabetes in 
2017 and this number is projected to rise to 629 million by 2045 [1]. Type 2 diabetes 
(T2D) accounts for 90% to 95% newly diagnosed diabetes. In the United States, 
approximately 30.3 million US people, or 9.4% of the U.S. population have diabetes and 
an estimated 33.9% of U.S. adults aged 18 years or older (84.1 million people) have 
prediabetes [2]. 
 Diabetes has been subdivided into type 1 diabetes and type 2 diabetes. Over the past 
decades, the concept of diabetes has developed into considering type 1 diabetes and type 
2 diabetes as two ends of a diabetes spectrum, with intermediates including maturity-
onset diabetes of the young (MODY), latent autoimmune diabetes in adults (LADA), 
maternally inherited diabetes and deafness (MIDD), gestational diabetes mellitus (GDM), 
and neonatal diabetes [3]. T2D is the most prevalent form, accounting for approximately 
90% of all diabetes cases [4]. The development of T2D is a progressive process caused 
by a complex interplay between environmental, epigenetic and genetic factors [3]. 
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Several environmental variables such as age, gender, central obesity, low physical activity 
and an unhealthy diet consisting of high saturated fatty acids and/or trans fatty acids and 
low dietary fiber, have been identified as risk factors for type 2 diabetes [4-6]. 
Heritability of T2D is estimated to be between 30% and 80% based on twin and familial 
studies [7-11]; the longest follow-up studies yield the highest estimates of up to 80% 
heritability of T2D [3]. Recent genetic studies, especially high throughput genome-wide 
association studies (GWAS), have identified a multitude of variants associated with T2D. 
To date, at least 68 regions on human genes have shown replicated association with T2D, 
or T2D related traits (e.g. glucose tolerance and insulin resistance) [12]. However, one 
primary limitation would be that of modest effect sizes of common variants, especially 
those identified through recent GWAS for T2D and most identified SNPs (single nuclear 
polymorphisms) that confer only 10–20% additional risk of T2DM with few exceptions 
with high odds ratios [3]. To date, TCF7L2 (Transcription factor 7-like 2) is one of the 
top diabetes candidate genes yielding high risk for T2D. Several genome-wide 
association studies and meta-analysis studies have repeatedly confirmed that variants in 
TCF7L2 are strongly associated with the susceptibility of type 2 diabetes in Caucasians 
and some Asian populations, conferring as high as 40% additional risk of T2D [12-18].  
TCF7L2 gene and protein structure 
TCF7L2 gene product is a transcription factor that belongs to a family of T-cell 
factor /lymphoid enhancer factor (TCF/LET) [19]. Proteins of the TCF/LEF family 
contain an 80-amino-acid high mobility group (HMG) box. HMG boxes bind DNA as 
monomers in a sequence-specific manner. TCF/LEFs bind to specific DNA sequences 
referred as Wnt responsive elements (WRE: CCTTTGA/TA/T) [20, 21]. TCF7L2 gene 
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spans a 215,863 bases region on chromosome 10q25.3 [22]. It has 17 exons, of which 
five exons (4, 13, 14, 15 and 16) are alternative yielding different slicing possibility [23]. 
Interestingly, the protein products detected by Western blotting in most tissues are 78 kDa 
and 55 kDa, suggesting the existence of undefined post-translational modifications [24]. 
Vacik et al [25] also found another brain-specific isoform in the mouse model. This form 
is a truncated isoform, defined as TCF7L2DN (dominant TCF7L2) that lacks β-catenin 
binding domain and that therefore acts as a potent dominant-negative Wnt antagonist.  
TCF7L2, a Wnt signaling pathway effector 
TCF7L2 together with β-catenin is a well-known biparticle transcription factor in 
the canonical Wnt pathway. The Wnt signaling pathway is a conserved pathway in 
animals and human beings, and its activity is ubiquitous and involved in numerous 
fundamental processes essential for embryonic development and normal adult 
homeostasis [26]. In the nucleus, β-catenin can bind members of the TCF/LEF family of 
transcription factors and recruit the transcriptional Kat3 co-activators p300 and/or CBP 
(CREB-binding protein) to transcribe Wnt target genes [27, 28]. Products of Wnt signal 
targeted genes have a plurality and diversity of biochemical functions including 
activation of cell cycle progression and proliferation, inhibition of apoptosis, cell 
differentiation, growth and migration cell cycle kinase regulation, cell adhesion, hormone 
signaling, and transcription regulation [29]. Mutations in Wnt genes or Wnt pathway 
components lead to specific developmental defects, and numerous human diseases, such 
as various types of cancer, Type 2 diabetes, obesity, bone density defect, coronary 
disease, etc. [1]. 
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Intensive effects to the function of the Wnt signaling pathway on glucose and 
metabolic homeostasis have been made immediately after recognition of the significant 
association between certain single nucleotide polymorphisms in TCF7L2 gene and the 
risk of T2D. Current findings revealed the potential role of TCF7L2 in the Wnt signaling 
pathway related to incretin hormone regulation, β-cell proliferation and apoptosis, and 
glucose production have been documented tissues [30-32]. In addition, more recent 
studies also revealed that potential role of TCF7L2 in adipogenesis and demonstrated 
variants in this gene could modify the risk of developing obesity and Metabolic 
Syndrome [33-36]. 
Wnt signaling pathway in incretin hormone regulation  
Incretins are a group of metabolic hormones that stimulate a decrease in blood 
glucose levels. Two main incretin hormones are glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), which are mainly secreted from 
gastro-intestinal K- and L-cells, respectively [30, 37]. They could directly stimulate the 
pancreatic β-cell, accounting for some 25-70% of postprandial insulin secretion in 
healthy subjects [38]. In patients with T2D, however, this effect is greatly reduced or lost 
due to a combination of severely impaired or eliminated insulinotrophic effect of GIP and 
reduced meal stimulated GLP-1 secretion. In addition to incretin insulinotropic effect, 
GLP-1 also possesses “insulin-like” or insulinomimetic effect on pancreatic β-cells and 
extra-pancreatic tissues or cell lineages and exert protective effects in pancreatic β-cells 
function and survival [39]. 
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Studies found that in intestinal L endocrine cells, expression of the proglucagon 
gene (GCG) and production of GLP-1 could be positively regulated by Wnt ligand, 
lithium, which mimics the activation of Wnt signaling while inhibition of glycogen 
synthase kinase-3beta, the major negative modulator of the Wnt pathway inhibiting GCG 
mRNA expression and GLP-1 synthesis [30, 40]. The regulatory role of Wnt signaling in 
gut GCG expression was further confirmed by using a constitutively active β-catenin 
mutant and dominant negative TCF7L2 [37, 40, 41]. Mechanistically, Wnt signaling is 
involved in the regulation of the proglucagon gene expression due to the binding of β- 
catenin/TCF7L2 to the G2 enhancer element of GCG promoter, demonstrated by 
quantitative chromatin immunoprecipitation [40]. Wnt signaling pathway is not only 
involved in GLP-1 expression, but also has effect on GIP transcription. Lithium or Wnt-3, 
as Win signal ligands, was shown to increase GIP transcription in intestinal endocrine K 
cells [42]. Thus, an alteration in Wnt signaling pathway caused by mutations on TCF7L2 
gene could potentially lead to an altered secretion of GLP-1 or GIP which, in turn, could 
have consequences for the insulin secretion following a meal. In support of this 
hypothesis, Lyssenko [43] found that in T2D patients with CT/TT genotypes of SNP 
rs7903146 showed increased mRNA levels of TCF7L2, associated with impaired insulin 
secretion and incretin effects. In parallel, Schafer [44] found that there is a significant 
reduction in GLP-1-induced insulin secretion in people with TCF7L2 risk alleles 
rs7903146 and rs12255372. Færch [45] found that healthy carriers with risk T allele of 
alleles rs7903146 have lower fasting GIP concentrations and lower total GIP secretion 
during the a 3-h oral glucose tolerance test (OGTT). This study suggests Wnt signaling 
and its effectors TCF proteins are not only involved in the production of both GLP-1 and 
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GIP, but also in the production of GLP-1 receptor and GIP receptor. Shu [46] found that 
GLP-1 receptor and GIP receptor was significantly reduced in isolated human islets when 
siRNA treatment was used to induce TCF7L2 depletion in islets. A recent study 
demonstrated TCF7L2 also regulates expression of GCG in the brain using transgentic 
mice with a functional knockdown of TCF7L2 [47]. Transgenic mice showed reduced 
brain GCG expression, impaired glucose tolerance and insulin sensitivity when fed a 
high-fat diet (HFD). Taken together these studies suggested that TCF7L2 may be an 
important mediator of the GLP-1 signaling pathway, and indicate a central action of 
TCF7L2 in control of glucose homeostasis.             
Wnt signaling pathway in β-cell proliferation and apoptosis 
The loss of functional β-cells is the root cause for the development of diabetes. 
Thus, the regulation of β-cell proliferation, differentiation and apoptosis is critical to 
maintain normal β-cell function and to promote adaptive growth of β-cells when the need 
for insulin increases. Previous studies have demonstrated that the Wnt signaling pathway 
plays critical roles in regulating multiple developmental processes, including proliferation 
of organ-specific stem/progenitor cell populations, growth control and cell fate 
determination in diverse organs, and tissue patterning [48]. In one study, Schinner and 
colleagues [32] found that human fat-cell conditioned medium stimulated the 
proliferation of a pancreatic β-cell line and primary mouse islet cells and stimulated 
insulin secretion from pancreatic β-cells, but the stimulation can be blocked by the Wnt 
repressor, secreted frizzled related protein 1. In another study, Shu [49] found that over-
expression of TCF7L2 could protect human or mouse pancreatic isolated islets from 
glucose- and cytokine-mediated apoptosis while in contrast, siRNA-mediated TCF7L2 
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depletion resulted in a significant increase in β-cell apoptosis and decrease in β-cell 
proliferation, associated with the attenuation of glucose-stimulated insulin secretion. 
Later on, Shu group [50] demonstrated TCF7L2 levels correlated with beta cell adaptive 
compensation in a HFD induced diabetic mouse model and TCF7L2 expression was 
increased together with pancreatic duct cell proliferation and differentiation. In addition, 
they found increased TCF7L2 levels correlated with insulin-positive ductal epithelial 
cells in patients with type 2 diabetes and TCF7L2 overexpression induced proliferation of 
pancreatic duct cells and islet-like cell cluster formation next to duct cells in human 
isolated exocrine tissue. Reports from other research groups also confirmed that TCF7L2 
protein levels were correlated with β-cell and able to improve β-cell survival, and 
regeneration [51, 52]. Interestingly, Yao and colleagues [53] found that geniposide, a 
nature occurring compound from Gardenia Fruits, was found to promote β-cell survival 
by increasing β-cell proliferation and decreasing β-cell apoptosis in cultured mouse islets 
after challenge with diabetic stimuli through upregulating β-catenin/TCF7L2 pathway. 
Collectively, these evidences support the role of Wnt signal in the β-cell homeostasis. 
TCF7L2’s role in gluconeogenesis from liver 
Blood glucose levels are maintained by the balance between glucose uptake by 
peripheral tissues and glucose secretion by the liver. Thus gluconeogenesis from liver 
plays a critical role in maintaining glucose homeostasis. Studies suggested TCF7L2 
might be a potential negative regulator of gluconeogenesis in the liver. Norton et al [54] 
demonstrated that interfering in Wnt signaling by silencing TCF7L2 led to increased 
basal levels of hepatic glucose production in a rat hepatic cell line, associated with the 
over-expression of genes that encodes key rate-limiting gluconeogenic enzymes including 
8 
 
fructose-1-6-bisphosphatase, phosphoenolpyruvate carboxykinase 1 and glucose 6-
phosphatase. In line with this finding, Oh et al [55] found that hepatic TCF7L2 
knockdown caused an increase in plasma glucose levels, which was associated with 
glucose intolerance and elevated hepatic gluconeogenic gene expression while 
overexpression of a nuclear isoform of TCF7L2 in HFD-fed mice improved glucose 
tolerance. In another study, Ip et al [56] utilized a transgenic mouse model named 
LTCFDN. In this mouse model, TCF7L2DN, as a negative Wnt regulator, was 
specifically produced in liver. LTCFDN mice exhibited progressive impairment in 
response to pyruvate challenge and hepatocytes displayed elevated gluconeogenic gene 
expression, gluconeogenesis, and loss of Wnt-3a-mediated repression of 
gluconeogenesis. These studies collectively supported Wnt signaling activation and 
TCF7L2 expression negatively regulated hepatic gluconeogenesis and imply variants in 
TCF7L2 gene may contribute to dysregulated glucose production in the liver. To support 
this hypothesis, Lyssenko et al [57] found that the risk T allele of SNP rs7903146 was 
also associated with enhanced rates of hepatic glucose production. In line with this 
founding, Pilgaard demonstrated that this risk allele was associated with elevated hepatic 
glucose production, even in patients undergoing a hyperinsulinemic clamp [58].  
Association between TCF7L2 and T2D 
The association between TCF7L2 gene and the risk of T2D was first discovered by 
deCODE group from an Iceland cohort study in 2006 [59]. They found that a 
microsatellite, DG10S478, located within the fourth intron region of the TCF7L2 gene, 
was strongly associated with T2D susceptibility. Later on a few other polymorphisms in 
this gene have been identified and reported to be significantly associated with T2D, and 
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majority of the significant polymorphisms were located within a genome area of 92-kb 
base pairs where the fourth intron and left flanking of the fifth intron are located within 
[60, 61]. Multiple lines of studies suggested this SNP-containing interval might exert an 
important role in regulation of TCF7L2 gene expression. Savic et al [62] demonstrated 
this region contains a strong regulatory enhancer by using bacterial artificial chromosome 
assay in a transgenic mice model. Kennell and Locke [63, 64] found that this region also 
contains a signal for alternative polyadenylation for production of a truncated, inhibitory 
TCF7L2 isoform lacking HMG DNA-binding domain. Moreover, another independent 
study identified that the fifth intron of the TCF7L2 gene harbors a highly conserved 
promoter Ex1b-e for a dominant-negative isoform of TCF7L2 which lacks the β-catenin 
binding domain [65]. However, the exact mechanism of how the polymorphisms in this 
gene influence gene production is not determined. So far, the association between 
TCF7L2 gene polymorphisms and T2D have been validated in several populations, with 
majority in populations of European ancestry [66, 67]. Generalization of results across 
multiple racial/ethnic groups helps confirm the relevance of some of these loci for the 
risk of T2D. Up to now, few existing studies have examined genetic predisposition to 
T2D in Hispanic populations. Most genetic studies were either carried in population of 
Mexican origin or treated Hispanic populations as a single group despite the diverse 
genetic and environmental background among Hispanic populations [68, 69]. Similarly, 
results from studies conducted in African Americans were sparse and inconsistent, 
partially due to genetic heterogeneity among Blacks [66].  
Food and Gene Interaction on T2D 
TCF7L2 has the largest effect among the various susceptibility genes on type 2 
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diabetes, such as KCNQ1, CDKN2B, FTO and HHEX/IDE [70]. However, inconsistent 
replication of results is often present when studying genetic associations, possibly due to 
ethnic diversity present in this complex interplay between genetic and environmental 
factors, especially dietary factors. The epidemic of T2D only dates back 50 years. It is 
quite clear that during this period the environmental factors have changed dramatically. 
This epidemic is highly possible not due to genetic changes since these take many 
generations to occur. A traditional high energy-burning lifestyle has been replaced by a 
sedentary lifestyle and consumption of an energy-dense diet, which is a common 
phenomenon worldwide, especially pronounced in the United States [3]. However, 
genetic variants could affect specific metabolic processes to make an individual more 
susceptible to the harmful effects of environmental factors such as high consumption of 
energy dense food and less physical activity [71].  
Previous studies have demonstrated that differences in intake of calories, dietary fat, 
high glycermic index carbohydrates, and certain micronutrients are linked to type 2 
diabetes [72]. Some recent explorations on such interplay between TCF7L2 gene 
polymorphisms and dietary factors have shown promising results. In the Diabetes 
Prevention program, the risk allele T of TCF7L2 rs7903146 showed a tendency towards 
being strongly associated with type 2 diabetes in the placebo group compared with the 
lifestyle-intervention group but the results did not reach statistical significance [73]. In 
the European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam cohort 
higher whole-grain intake was found to be protective against type 2 diabetes among SNP 
rs7903146 CC genotype carriers but not among T allele carriers [74]. In Nurses' Health 
Study, the TCF7L2 risk allele was reported to have a stronger association with type 2 
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diabetes among individuals with higher dietary glycaemic load and glycaemic index [14]. 
In the Tübingen Lifestyle Intervention Program (TULIP) described an interaction 
between dietary fiber and the TCF7L2 rs7903146 risk variant with regard to successful 
weight loss after a lifestyle intervention [75]. In another study from Sweden, Hindy et al. 
[76] used a cohort of nearly 25,000 initially nondiabetic Swedish adults to assess 
interactions between dietary fiber and the TCF7L2 rs7903146 variant on T2D incidence. 
The authors reported a nominally statistically significant interaction between the TCF7L2 
SNP rs7903146 and dietary fiber intake in T2D risk. Another recent study found 
consumption of Mediterranean diet could modify the association between TCF7L2 risk 
allele and weight gain, and suggested a beneficial effect of the Mediterranean diet in 
subjects with TCF7L2 risk allele(s) [77].  Thus, it will be of great interest to investigate 
the interplay between dietary factors and genetic variants in modifying the risk to T2D 
development.  
Diabetes and Ethnicity 
Compared to the general population, African Americans are disproportionately 
affected by diabetes. 12.7% of African Americans aged 18 years or older have diabetes, 
compared to 7.4% of non-Hispanic whites in 2015 [2]. African Americans are almost 
twice as likely to be diagnosed with diabetes as non-Hispanic whites. In addition, they 
were more likely to suffer from complications of diabetes, such as high blood pressure 
end-stage renal disease and lower extremity amputations and were twice as likely as non-
Hispanic Whites to die from complications of diabetes [78]. Because of the high 
prevalence of diabetes in the African American community, it has been suggested that 
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African Americans may be more susceptible to the disease compared with Whites 
through direct genetic propensity or gene–unfavorable environment interactions (e.g. 
high in fat, sugar, and salt and low in fruits and vegetables) [79]. Although associations 
between various SNPs in TCF7L2 and the risk of T2D have been observed across 
ethnically diverse populations [66], results from studies conducted in African Americans 
have been sparse and inconsistent. Moreover, the ethnic diversity within ‘Black’ 
population is not yet explored.  
In general, Hispanics are at high risk for developing type 2 diabetes and related 
cardio-metabolic abnormalities. According to CDC report, Hispanic populations have a 
higher age-adjusted rate of diagnosed diabetes (12.1%), compared to7.4% of non-
Hispanic Whites [2]. Among Hispanic population, Cuban Americans represent the third 
largest minority group in the United States and has the highest proportion of the elderly 
population (26% for age 55 or older) compared to other Hispanic groups (11.9% for 
Mexicans and 16.1% for Puerto Rican) [70]. Although Cuban Americans (9.0%) have a 
lower prevalence of T2D than Mexicans (13.8%) and Puerto Ricans (12.0%) but still 1.22 
times higher than non-Hispanic whites (7.4%) and a highest proportion of diabetes as the 
underlying cause of death (44%) as compared to other Hispanics groups (39% for Puerto 
Ricans and 37% for Mexican Americans) [34, 80]. By far, existing studies have examined 
genetic association with T2D in Hispanic subgroup, of which majority were carried on in 
populations of Mexican origin [66, 81, 82]. The current Cuban population resulted from 
the complex process of racial mixture from Asian, African, European and Native 
American [83]. The genetic heritage from these populations might play an important role 
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for the higher prevalence of T2D and T2D related complications in Cuban Americans. In 
addition, the disproportionally affected rates of T2D in Cuban Americans could be 
ascribed to complex interaction of genetic predisposition with acculturation related 
unhealthy diet behavior (e.g. higher sugar and low fiber) but few studies have been 
conducted in this area [16].   
Haitian Americans are one of the fastest growing Caribbean immigrant populations 
in the United States. According to the United States Census, an estimated 929,074 Haitian 
Americans were living in the U.S. in 2013, of which approximately half of them reside in 
Florida, and nearly one third (~290,000) live in the Miami metro area [84]. Haitian 
Americans are one of the high-risk populations for T2D. Though official data for Haitian 
Americans are not available, due to being grouped with other Blacks, a small-scale study 
conducted in a Haitian community (Little Haiti) in the Miami-Dade County, FL, 
estimated a 33% prevalence of diabetes among Haitian immigrants [85]. Haitian 
Americans have specific characteristic in their genetic background and lifestyle which 
distinguish them from African Americans. Apart from being African descent, populations 
of Haitian Americans also have lineage from France, and Spain [86]. Haitian Americans 
have unique dietary pattern featured by two meals a day with starch predominantly as 
energy source. These features might partially explain why Haitian Americans have poorer 
glycemic control than African Americans and non-Hispanic Whites with diabetes [87]. In 
addition, another study on eating behavior showed that Haitian Americans and African 
Americans have significantly different healthy eating index (HEI) scores, and levels of 
physical activity [88]. Studies from our research group also suggested that Haitian 
Americans may have different genetic makeup than African Americans [29]. These 
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unique features distinguish Haitian Americans as a unique ethnic group in South Florida 
and but very often they were grouped with other Blacks with African origins for health 
research. Thus, translation and generalization of the results from genetic association 
conducted in African Americans to Haitian Americans should be done with caution and 
warrants further replication. By far, studies looking at health disparity in a separated 
Haitian American population is limited, including genetic studies. Further investigation is 
needed to expand current knowledge.  
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Specific aims and hypotheses 
The TCF7L2 gene product is a high-mobility box-containing transcription factor 
which is a ubiquitous protein that belongs to a family of T-cell factor /lymphoid enhancer 
factor (TCF/LET) [1]. TCF7L2, together with β-catenin is a well-known bipartite 
transcription factor in the canonical Wnt pathway. Great efforts have been devoted to 
elucidating the potential role of TCF2L2 in the Wnt signaling pathway related to incretin 
hormone regulation, β-cell proliferation and apoptosis, and hepatic glucose production [2-
4]. The involvement of TCF7L2 in all these pathway puts this gene in a critical role 
suggesting strong relationship of polymorphisms of TCF7L2 with type 2 diabetes (T2D). 
So far, some SNP loci on this gene have proved to be associated with type 2 diabetes in 
various ethnic groups (e.g. Caucasian, East Asian, Indian, and Middle East) [5].  
However, inconsistent replication of results is often present when studying genetic 
associations, due to ethnic diversity present in the complex interplay between genetic and 
environmental factors. Compared to the general population, African Americans are 
disproportionately affected by diabetes. 12.7% of African Americans aged 18 years or 
older have diabetes, compared to 7.4% of non-Hispanic whites in 2015 [6]. African 
Americans are almost twice as likely to be diagnosed with diabetes as non-Hispanic 
whites. Because of the high prevalence of diabetes in the African American community, 
it has been suggested that African Americans may be more susceptible to the disease 
compared with Whites through direct genetic propensity or gene–unfavorable 
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environment interactions (e.g. high in fat, sugar, and salt and low in poor in fruits and 
vegetables) [7]. Haitian Americans are usually grouped together with other populations of 
African origins in population based studies. However, Haitian Americans have specific 
characteristic in their genetic background and lifestyle which distinguish them from 
African Americans and may contribute inconsistent results in gene association study due 
to population stratification in Black people [8]. So far, only two studies from our group 
have investigated the genetic predisposition on diabetes (vitamin D receptor gene and 
PPARGC1A gene) in Haitian Americans. Further investigation is needed in this area to 
expand current knowledge. Similarly, Hispanic populations also have a high age-adjusted 
rate of diagnosed diabetes (12.1%) [6]. Although Cuban Americans (9.0%) has a lower 
prevalence of T2D than Mexicans (13.8%) and Puerto Ricans (12.0%) but still 1.22 times 
higher than non-Hispanic whites (7.4%) and a highest proportion of diabetes as the 
underlying cause of death (44%) as compared to other Hispanics groups (39% for Puerto 
Ricans and 37% for Mexican Americans [9, 10]. The current Cuban population resulted 
from the complex process of racial mixture from Asian, African, European and Native 
American [11]. Data showed that those minority groups have a higher diabetes rate 
compared to their white counterparts [12]. Thus, the genetic heritage from these 
populations might play an important role for the higher prevalence of T2D in Cubans 
Americans. In addition to possible genetic differences, studies suggest higher 
consumption of junk foods and low consumption in fruits and vegetables among Cuban 
Americans [13, 14]. All of these factors make Cuban Americans an interesting population 
to study. However, few studies have looked at genetic associations of Cuban Americans 
with T2D. Therefore, due to aforementioned gap in knowledge, this study is aimed to 
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assess six TCF7L2 common polymorphisms (table 1): rs7903146, rs12255372, 
rs11196205, rs7901695, rs7895340 and rs4506565, in relation to T2D and related 
phenotypes in three race/ethnic populations (African Americans, Haitian Americans and 
Cuban Americans) at high risk for T2D and potential environmental modification factors. 
Three hypotheses were tested in this dissertation: 1) there would be a significant 
association between TCF7L2 risk-conferring variants and type 2 diabetes prevalence in 
each of three ethnic populations; 2) TCF7L2 risk-conferring genotypes would be 
significantly associated with impaired beta-cell function, insulin sensitivity and insulin 
resistance in each of three ethnic populations; 3) different environmental factors would 
modify associations between TCF7L2 variants and the risk of type 2 diabetes among each 
of three ethnic populations. 
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Table 1. Characteristics of studied SNPs in the TCF7L2 gene 
NCBI ref 
SNP 
number* 
Chromosome 
nucleotide position† 
Location Polymorphisms 
Minor 
allele 
Minor allele 
frequency& 
EUR AFR AMR 
rs7901695  Chr. 10: 112994329 intron  T/C C 0.34 0.44 0.26 
rs4506565  Chr. 10: 112996282 intron  A/T T 0.35 0.44 0.26 
rs7903146  Chr. 10: 112998590 intron  C/T T 0.32 0.26 0.24 
rs7895340  Chr. 10: 113041766 intron  A/G G 0.48 0.18 0.34 
rs11196205  Chr. 10: 113047288 intron  C/G G 0.49 0.18 0.35 
rs12255372 Chr. 10: 113049143 intron  G/T T 0.29 0.30 0.22 
*National Center for Biotechnology Information (NCBI) reference single nucleotide polymorphism 
(SNP) number (http://www.ncbi.nlm.nih.gov/) †Genome Reference Consortium Human Build 38 
patch release 7 (GRCh38.p7) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP) 
&Information of Minor allele frequencies are obtained from 1000 Genomes Project 
(http://www.internationalgenome.org). Population descriptors: EUR: European; AFR: African; 
AMR: Ad Mixed American.  
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CHAPTER II    THE VARIANTS IN THE TCF7L2 GENE ARE ASSOCIATED 
WITH THE RISK OF TYPE 2 DIABETES IN CUBAN AMERICANS 
Abstract 
Objectives: Type 2 diabetes (T2D) is a complex and chronic metabolic disorder that 
involves complex interaction between environmental factors and genetic predisposition. 
TCF7L2 gene recently emerged as a top candidate gene for T2D. Our study is aimed to 
assess six common polymorphisms in TCF7L2 gene: rs7901695, rs4506565, rs7903146, 
rs11196205, rs7895340 and rs12255372, in relation to the risk of T2D and related 
phenotypes in Cuban Americans who lived in Miami-Dade and Broward counties, 
Florida. 
Methods: We conducted a case-control study with 341 Cuban Americans (172 without 
T2D /169 with T2D). Unconditional logistic regression method was used to assess the 
association between six TCF7L2 polymorphisms and the risk of T2D in three genetic 
models adjusted by potential confounding factors such as age, sex, BMI, physical 
activities and calorie intake. Student’s t-tests on continuous values of T2D related 
quantitative traits were compared between risk allele carriers and non-carriers in control 
subjects. In addition, linkage disequilibrium and haplotype analysis were performed using 
Haploview 4.2. 
Results: Four TCF7L2 SNPs (rs7901695, rs4506565, rs7903146 and rs11225537) were 
significantly associated with the risk of T2D in a Cuban American population after 
multivariable adjustment. We also found that among non-diabetic control subjects, risk 
minor allele carriers of three TCF7L2 SNPs (rs7901695 (T>C), rs4506565 (A>T) and 
rs7903146 (C>T)) had significantly higher fasting glucose level and marginally higher 
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level of glycated hemoglobin (A1C), compared to non-risk allele carriers. Consistently, 
results from haplotype analysis showed that two haplotypes TAC and CTT, formed by 
aforementioned three TCF7L2 SNPs (rs7901695, rs450565 and rs7903146), were 
significantly associated with the risk of T2D (p=0.0094, and p=0.0044, respectively), 
with the frequency of TAC significantly lower and CTT significantly higher in subjects 
with T2D, compared to subjects without T2D. 
Conclusions: The result of this study provides convincing evidence that variants in 
TCF7L2 gene confers strong susceptibility to T2D in the population studied. 
Introduction 
Type 2 diabetes (T2D) is a complex, multi-factorial metabolic disorder characterized 
by hyperglycemia resulting from impaired pancreatic beta cell function, decreased action 
of insulin on target tissues, or both [1].  Heritability of T2D is estimated to be between 
30% and 80% based on twin and familial studies [2-6]. Recent genetic studies, especially 
high throughput genome-wide association studies (GWAS), identified a multitude of 
variants associated with T2D. TCF7L2 (Transcription factor 7-like 2) is one of the top 
candidate genes yielding high risk for T2D. The TCF7L2 gene product is a high-mobility 
box-containing group (HMG) transcription factor which is a ubiquitous protein that 
belongs to a family of T-cell factor/lymphoid enhancer factor [7]. TCF7L2, together with 
β-catenin is a well- known bipartite transcription factor in the canonical Wnt pathway. 
Studies suggested TCF7L2 involvement in incretin hormone regulation, β-cell 
proliferation, apoptosis, and hepatic glucose production via Wnt signal pathway [8-10]. 
Strong associations between SNPs in TCF7L2 and the risk of T2D had been 
repeatedly detected in multi-ethnic groups, but few existing studies have examined this 
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association in Hispanic subgroup, of which majority were carried in populations of 
Mexican origin [11-13]. Cuban Americans represent the third largest minority group in 
the United States, and two thirds live in the state of Florida and over 50% lived in Miami-
Dade County. Approximately 16% of Cuban Americans ages 45-75 years in the US have 
diabetes which is 1.3 times higher than non-Hispanic Whites [14]. The disproportionally 
affected rates of T2D in Cuban Americans could be partially ascribed to increased genetic 
predisposition but few studies have been addressed in this area. One genetic study 
conducted by our research group demonstrated that peroxisome proliferator-activated 
receptor-γ coactivator 1- α (PPARGC1A) SNP rs7656250 (T>C) was significantly 
associated with the risk of T2D (OR=6.87, p=0.02) in Cuban Americans [15]. 
A serial of meta-analyses on the association between SNPs in TCF7L2 gene and the 
risk of T2D discovered that several polymorphisms, including SNP rs7901695, SNPs 
rs4506565 and rs7903146 (all of which are located within the fourth intron); SNPs 
rs7895340, rs11196205, and rs12255340 (all of which are located within the fifth intron), 
are consistently replicated by studies [12, 16-18]. However, the evidence to support the 
role of TCF7L2 gene polymorphisms related to the risk of T2D in Cuban Americans is 
limited. Therefore, the purpose of this study was to examine six most studied SNPs in 
TCF7L2 gene: rs7903146, rs12255372, rs11196205, rs7901695, rs7895340 and 
rs4506565 in relation to the risk of T2D and T2D related phenotypes in a Cuban 
American population. 
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Methodology 
Subjects 
This was a case-control study. The target population was Cuban American adults in 
Broward and Miami-Dade Counties, Florida. Approximately half of the participants had 
type 2 diabetes and the rest were free of diabetes. Participants were initially recruited 
from randomly generated mailing lists. The lists of addresses were purchased from 
Knowledge Base Marketing, Inc., Richardson, TX, U.S. Throughout a one-year period, 
ten thousand letters, along with an invitation flyer in both English and Spanish, were 
mailed to Cuban Americans. Of the participants who received letters, 4% (n = 388) 
responded. To ascertain T2D status, each participant was asked for the age of diagnosis 
and initial treatment modalities. Only 18 out of 388 subjects did not qualify for the study: 
for not being Cuban Americans (n= 2), age younger than 30 years (n= 9), and having 
other chronic illnesses (n=7). Validated questionnaires were used to collect information 
on demographics, dietary intake and physical activities [19-21]. Participants were 
instructed to fast at least 8 hours prior to their blood collection. A written consent was 
obtained for this study. Subjects with T2D were matched for age and gender with subjects 
without diabetes. This study was approved by the Institutional Review Board at Florida 
International University (FIU). Seven participants reported not having diabetes but were 
reclassified because their lab results classified them as having T2D according to 
American Diabetes Association (ADA) standards. These subjects were given their 
laboratory results and referred to their physicians. For the present study, we included 341 
subjects (172 with T2D /169 without T2D) due to biospecimen availability. 
 
31 
 
Anthropometric measurements and biospecimen analyses 
Height, weight, and blood pressure were measured using standard methodology 
[14]. Twenty ml of venous blood was collected from each participant after an overnight 
fast (at least 8 hours) by a certified phlebotomist. Glucose levels in serum were quantified 
using hexokinase method. Whole blood was used to measure glycated hemoglobin (A1C) 
using Roche Tina Quant method (Laboratory Corporation of America, Lab Corp, FL). 
Automatic chemical analyzer was employed to determine high-density lipoprotein 
cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG) 
and total cholesterol (TC). Serum insulin levels were determined using the Human 
Insulin ELISA kit from Millipore (St Charles, MZ, USA). The updated homeostatic 
model assessment (HOMA2) is based on the Oxford University HOMA2 calculator 
(www.ocdem.ox.ac.uk) and is used to calculate HOMA2 indexes: HOMA2_IR 
(homeostatic model assessment of insulin resistance), HOMA2_IS (homeostatic model 
assessment of insulin sensitivity) and HOMA2_B (homeostatic model assessment of β-
cell function) [22]. 
Isolation of DNA and genotyping 
Genomic DNA was isolated from the whole blood using QIAamp DNA Blood mini 
kit (Qiagen, Hilden, Germany), according to the vender’s recommended protocol. Quality 
and quantity of the isolated DNA was assessed by using 2000c nanodrop 
spectrophotometer (Thermo Scientific, USA). Genotyping for all six SNPs was 
performed by real-time PCR amplification on BioRad CFX96 real time PCR instrument 
(Hercules, CA, USA) using commercially available TaqMan allelic discrimination assays 
(LifeTech, Foster City, CA, USA). To ensure reproducibility and reliability of genotyping 
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method, 10% of the DNA samples was duplicated during genotyping. We obtained a 
100% concordance between the genotyped duplicate samples for the single nucleotide 
polymorphism (SNP).  
Statistical Analysis 
Statistical analysis was conducted using SAS version 9.4 (SAS Institute Inc., Cary, 
NC, USA).  All statistical tests were two-tailed, and the threshold for statistical 
significance was set at P≤0.05. Current sample size has 80% statistical power for 
significance threshold of 0.05. Genotype counts in each SNP was checked for Hardy-
Weinberg equilibrium (HWE) in controls using the Chi-squared goodness-fit test. The 
distributions of the T2D related quantitative traits, such as HOMA2 index, FPG, A1C, 
etc., were markedly skewed, which were normalized, to a large extent, by their 
logarithmic transformation. Therefore, student’s t-tests on continuous values of these 
quantitative traits were performed on logarithmically transformed values. Demographic 
and clinical information between cases and controls was compared using student’s t-test 
for continuous variables, and Chi-squared test for categorical variables. All genetic 
associations were assessed by using the three genetic models: dominant, additive and 
recessive model. Logistic regression models were used to calculate unadjusted and 
adjusted odds ratio (OR) and 95% confidence intervals (CIs) to assess the relationship of 
all SNPs with binary outcome for case-control status (T2D=Yes/No) before and after 
adjusting for potential confounding factors such as age, sex, body mass index (BMI), 
physical activities and calorie intake. Linkage disequilibrium and haplotype analysis were 
performed using Haploview 4.2 (Cambridge, MA, USA) [23].  
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Results 
This study included N=341 Cuban Americans (n=222 female and n=119 male) with 
(n=172) and without (n=169) T2D. Characteristics of the participants were presented as 
comparison of means±SD by diabetes status (Table 1). The mean of age among 
participants without diabetes was 62.98±10.85 and 65.05±11.95 for participants with 
diabetes. Compared to adults without diabetes, significantly higher values in the 
following attributes are found in adults with diabetes: waist circumference, body mass 
index, HDL-cholesterol, fasting plasma glucose, AIC (%), insulin, and HOMA2_IR, 
while adults with diabetes had significantly lower diastolic blood pressure, triglycerides, 
HOMA2_B, HOMA2_IS, total kcal intake and weekly physical activities. 
Table 2 shows the distribution of allele frequencies and the genotypes of three 
genetic models in studied population. The genotypic distribution for each of the SNPs 
was in agreement with the predicted Hardy-Weinberg equilibrium in subjects without 
T2D (controls). Results showed that for the SNP rs12255372 (G>T), additive model, 
recessive model and allele frequency demonstrated significant differences between 
subjects with T2D and controls (p=0.0005, p=0.0002 and p=0.0004, respectively); the 
risk genotype TT and the T allele of the SNP rs12255372 was significantly higher in 
subjects with T2D than in controls. Similar significant results were also found for SNP 
rs7903146 (C>T), rs7901695 (T>C), and rs4506565 (A>T). We didn't find any significant 
results for SNP rs11196205 and rs7895340. 
Table 3 shows results from unconditional logistic regression with/without 
adjustment by covariates (BMI, age, gender, physical activity, and calories intake) in 
three genetic models. Consistent with the results from genotype distribution analyses, all 
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four above mentioned SNPs showed significant results in at least two genetic models. 
After multivariable adjustment, the results stayed significant. Of note, the significance 
increases from dominant model, to additive model and to recessive model, with recessive 
model showing the most significant results. For the SNP rs12255372 (G>T), the adjusted 
odds ratio (aOR) in the additive model was 3.24 (p=0.0026) for carrying the risk TT 
genotype, compared to subjects with GG genotype. For the SNP rs7903146 (C>T), the 
aOR in additive model was 2.57 (p=0.014) for carrying the risk TT genotype, compared 
to subjects with CC genotype. For SNP rs7901695 (T>C), the aOR in additive model was 
2.31 (p=0.018) for carrying the risk CC genotype, compared to subjects with TT 
genotype. For the SNP rs4506565 (A>T), the aOR in additive model was 2.38 (p=0.016) 
for carrying the risk TT genotype compared to subjects with AA genotype. We didn't find 
any significant results for TCF7L2 SNP rs11196205 and rs7895340, with or without 
multivariable adjustment. 
Table 4 shows T2D related metabolic traits between non-risk allele carriers and risk 
allele carriers of SNP rs7903146, SNP rs7901695 and SNP rs4506565 in non-diabetic 
controls. For all three SNPs, the fasting glucose level was significantly lower in non-risk 
allele carriers, compared to the risk allele carriers (p=0.019, p= 0.013 and p=0.011, 
respectively). Higher level of A1C was also observed in allele carriers of all three SNPs 
with marginal significance (p=0.069 p=0.067, and p=0.089, respectively).  
In the haplotype-based case-control analyses, two blocks were defined by using Four 
Gamete method (Figure 1) [24]. The first block was established by three consecutive 
SNPs: rs7901695, rs450565 and rs7903146. The second block was established by two 
consecutive SNPs: rs7895340 and rs11196205. SNPs within each block were in a strong 
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linkage disequilibrium. The haplotype association test identified two haplotypes TAC 
(frequency=56.4%, p=0.0094) and CTT (frequency=39.8%, p=0.0044) within the first 
block were strongly associated with the risk of T2D, with TAC haplotype significantly 
lower and CTT haplotype significantly higher in participants with T2D, when compared 
to controls. After performing permutation test (n=1000), the significance remained for the 
two haplotype combinations (p=0.045, and p=0.031, respectively) 
Discussion 
Our study found that out of 6 SNPs, four SNPs (rs7901695, rs4506565, rs7903146 
and rs1125537) in TCF7L2 gene were significantly associated with the risk of T2D in a 
Cuban American population. The association between the TCF7L2 gene polymorphisms 
with T2D stayed significant after multivariable adjustments. In addition, we also found 
that in the non-diabetic controls, risk minor allele carriers of three TCF7L2 SNPs 
(rs7901695 (T>C), rs4506565 (A>T) and rs7903146 (C>T) had significantly higher 
fasting glucose level and a marginally significantly higher A1C%, compared to non-risk 
allele carriers. To the best of our knowledge, this was the first study to validate six 
previously most studied SNPs in TCF7L2 gene in relation to the risk of T2D and T2D 
related quantitative traits in a homogeneous Cuban American population. 
TCF7L2 gene spans a 215,863 bases region on chromosome 10q25.3 [25], and has 
17 exons, of which five are alternative yielding different slicing possibility [26]. The 
association between TCF7L2 gene and the risk of T2D was first discovered by deCODE 
group from an Iceland cohort study in 2006 [27]. They found that a microsatellite, 
DG10S478, located within the fourth intron region of the TCF7L2 gene, was strongly 
associated with T2D susceptibility. Later on a few other polymorphisms in this gene have 
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been identified to be significantly associated with the T2D. Most significant 
polymorphisms were located within a genome area of 92-kb base pairs where the fourth 
intron and left flanking of the fifth intron are located within [28, 29]. Multiple lines of 
studies suggested this SNP-containing interval might exert an important role in regulation 
of TCF7L2 gene expression. Savic et al. demonstrated this region contains a strong 
regulatory enhancer by using bacterial artificial chromosome assay in a transgenic mice 
model [30]. Kennell and Locke research group found that this region also contains a 
signal for alternative polyadenylation for production of a truncated, inhibitory TCF7L2 
isform lacking HMG DNA-binding domain [31, 32]. Moreover, another independent 
study identified that the fifth intron of the TCF7L2 gene harbors a highly conserved 
promoter Ex1b-e for a dominant-negative isoform of TCF7L2 which lacks the beta-cat 
binding domain [33]. Studies proposed that the variants on TCF7L2 gene might have 
direct or indirect effect on incretin hormone regulation, β-cell function, and hepatic 
glucose production [9, 34, 35].  However, the exact mechanism of how the 
polymorphisms in this gene influence gene production is not fully discovered.  
Among TCF7L2 gene association studies with T2D and T2D related phenotypes, 
SNP rs7903146, which is located within the fourth intron, is the most studied and 
consistently replicated [35, 36]. By far, there is only one GWAS study in Hispanic/Latino 
individuals included Cuban American as a subgroup and showed that SNP rs7903146 in 
TCF7L2 gene reached genome-wide significance [11]. Consistently with this finding, the 
present study found SNP rs7903146 was significantly associated with the risk of T2D in 
Cuban Americans. We found the risk allele T was significantly higher in participants with 
T2D than controls, and the risk TT genotype carriers have a 157 % increased risk of 
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developing T2D compared to non-risk allele carriers under the additive model. To date, 
the exact mechanism through which the SNP rs7903146 influenced the glucose 
homeostasis is not fully understood. Previous function studies regarding this SNP showed 
that T2D patients with CT/TT genotypes had increased mRNA levels of TCF7L2, 
associated with impaired insulin secretion and incretin effects [37]. Lyssenko also found 
that the risk T allele of SNP rs7903146 was associated with enhanced rates of hepatic 
glucose production. Schafer et al. found that there is a significant reduction in glucagon-
like peptide-1-induced insulin secretion in people with risk alleles of SNP rs7903146 
[38]. In the present study, we found SNP rs7903146 risk allele carriers had a significantly 
higher fasting glucose and a higher A1C (marginally significant), compared to non-risk 
allele carriers in non-diabetic controls. The Population Architecture using Genomics and 
Epidemiology (PAGE) study found that the SNP rs7903146 risk allele T was marginally 
significantly associated with increased fasting glucose level in European Americans but 
no association was found in Mexican Americans [39]. Another recent evidence also 
linked SNP rs7903146 risk allele T to altered blood glucose levels [40]. They found that 
T allele carriers of SNP rs7903146 had increased mean nocturnal glucose level, compared 
to non-T allele carriers. In addition, a genome-wide association meta-analysis has 
identified SNP rs7903146 has a strong significant association with of AIC% in three 
isolated populations: the Orkney Isles in the north of Scotland, the Dalmatian islands of 
Vis, and Korčula in Croatia [41]. Together, those evidence suggested that SNP rs7903146 
has a potential impact on glucose homeostasis, possibly through the pathways mentioned 
above and warrants further investigations in Cuban American population.  
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Another most validated SNP in TCF7L2 gene is SNP rs12255372. Based on a recent 
data analysis, twenty-four (60.0%) of the 40 studies showed significant positive 
associations, with the summary OR of 1.33 (95% CI: 1.27–1.40) [42]. So far, few studies 
investigated this SNP with the risk of diabetes in Hispanic populations, and results are 
inconsistent. A study of Mexican Americans showed that SNP rs12255372 of TCF7L2 
was significantly associated with the risk of gestational diabetes and interacts with 
adiposity to alter insulin secretion [43], whereas another study in Venezuelans showed 
that no significant association between SNP rs12255372 and the risk of T2D [44]. 
Another study in Mexican children showed that SNP rs12255372 TT genotype, generally 
considered as risk-conferring genotype for T2D in most previous studies, was 
significantly associated with lower fasting plasma glucose and lower homeostasis model 
of insulin resistance (HOMA2-IR) [45]. In our study, SNP rs12255372 allele T yielded a 
significant association with the risk of T2D. The risk allele T was significantly higher 
(p=0.0004) in patients with T2D compared to controls, and TT genotype carriers had 
224% higher risk of developing T2D compared to non-risk allele carriers under the 
additive model. Based on the present study, results from our study indicated the 
independent contribution of SNP rs12255372 to the risk of T2D in the Cuban American 
population and suggested potential population stratification effect and consequently 
biased results when treating the heterogeneous Hispanic population as a single population 
for genetic studies [46].  
In addition, we also identified two other SNPs rs4506565 and SNP rs7901695 that 
are significantly associated with the risk of T2D in Cuban Americans. The minor alleles 
in both SNPs (rs4506565 (A>T) and rs7901695 (T>C)) were significantly higher in 
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subjects with T2D than controls, and the homozygous minor allele genotype of SNP 
rs4506565 carriers have a 138 % increased risk of developing T2D compared to non-risk 
allele carriers under the additive model while 131% increased risk for participants with 
the homozygous minor allele genotype of SNP rs7901695. Previous studies in Caucasian 
and Asian populations observed significant association between these two SNPs and the 
risk of T2D [12]. To our best knowledge, only one genetic study on SNP rs7901695 and 
one on SNP rs4506565 confirmed their association to the risk of gestational diabetes in 
the Hispanic/Latino population [12, 42]. The missing association between these two 
SNPs and T2D in the Hispanic population could be due to different genetic architecture 
of sub-Hispanic groups. The relationship between these two SNPs and the risk of T2D is 
yet to be determined in Cuban Americans. Two functional investigations showed that 
SNP rs7901695 risk alleles is significantly associated with the increased proinsulin: 
insulin ratio and suggested this risk variants detrimental influence on beta-cell functions 
[36, 47]. In line with these findings, our study demonstrated that the fasting glucose level 
is significantly higher, as well as A1C level marginally significantly higher in risk-allele 
carriers of SNP rs7901695, compared to the non-risk allele carriers in participants 
without T2D. In our study, SNP rs4506565 located in a strong linkage disequlibrium with 
SNP rs7901695 (r2=0.99). As expected, similar significant results were found for SNP 
rs4506565. The association between SNP rs4506565 and the risk of T2D have been 
previously reported in some studies, but few attempts have been made to explore the 
underlying mechanism for this association, which warrants further investigation [48-50]. 
One study conducted in Indian patients with T2D who were treated with sulfonylureas 
suggested that carriers with SNP rs4506565 TT genotype has a higher success rate of 
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treatment under the recessive model [51]. In our study, results from pairwise linkage 
disequilibrium analysis showed that these two SNPs (rs7901695 and rs4506565) are in a 
strong linkage disequilibrium with SNP rs7903146 (r2=0.863). Two haplotypes TAC and 
CTT, formed by these three TCF7L2 SNPs (rs7901695, rs450565 and rs7903146), were 
strongly associated with the risk of T2D (p=0.0094, and p=0.0044, respectively) in our 
studied population, with the frequency of TAC significantly lower and CTT significantly 
higher in subjects with T2D, compared to controls. The results of the haplotype analysis 
were consistent with the results from individual SNP analysis that C allele of SNP 
rs7901695, T allele of SNP rs4506565 and T allele of SNP rs7903146 were the risk 
alleles for T2D in our studied population. 
Our study has several strengths. T2D is a heterogeneous disorder with contributions 
from peripheral insulin resistance and β-cell dysfunction. In the present study, in addition 
to the association analyses of TCF7L2 SNPs in relationship to the risk of T2D, we also 
investigated some T2D related quantitative intermediate phenotypes (e.g. fasting glucose 
level and A1C) in control subjects. The consistent results from both analyses validated 
our findings. More than half of Cuban Americans who live in the United States are 
geographically concentrated in Miami-Dade and Broward Counties, Florida [52]. In this 
study, both cases and controls were selected from the same population pool and 
geographic area, with information on ethnicity up to two generations. Also, over 95% of 
our participants were white Cuban Americans. Together, these make our sample a 
relatively homogenous which consequently reduced the possibility of gene admixture 
with other ethnicities and the false positive rate due to population stratification [53]. This 
study also has some limitations. When we conducted the analyses on T2D related 
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quantitative traits in control subjects, due to the relatively small sample size in control 
group, the genetic variants with modest effect on the T2D related quantitative traits might 
be omitted. As the study was focused on the one gene, the influence of gene-gene 
interactions was not considered. Due to all of our participants recruited from Miami 
metropolitan area, the generalization of our results to other Cuban Americans residing 
outside this area should be made with caution and need further validation. 
Conclusions 
We found that of the six SNPs, four SNPs (rs7901695, rs4506565, rs7903146 and 
rs1125537) in the TCF7L2 gene were significantly associated with the risk of T2D in 
Cuban Americans living in Broward/Miami-Dade counties, Florida. After multivariable 
adjustment, the association between the TCF7L2 gene polymorphisms with the risk of 
T2D remained significant. We also found that among non-diabetic controls, risk minor 
allele carriers of SNP rs7901695 (T>C), SNP rs4506565 (A>T) and SNP rs7903146 
(C>T) have significantly higher fasting glucose level and a marginally significantly 
higher A1C% level, compared to non-risk allele carriers. In addition, we identified two 
haplotypes TAC and CTT, formed by three TCF7L2 SNPs (rs7901695, rs450565 and 
rs7903146), were strongly associated with the risk of T2D (p=0.0094, and p=0.0044, 
respectively), with the frequency of TAC significantly lower and CTT significantly 
higher in subjects with T2D, compared to controls. Validation and generalization of the 
results from previous genetic studies of other ethnic populations provide important public 
and clinical implications in T2D prevention and treatment in Cuban American population. 
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Table 1. Anthropometric and demographic characteristics of all participants 
 Without T2D 
(n=172) 
 With T2D 
(n=169) 
p* value 
Age (Years) 62.98±10.85 
 
65.05±11.95 0.095 
Female (N (%)) 115 (66.86%)  107 (63.31%) 0.49 
BMI (kg/m2)  29.58±1.18 
 
30.92±1.22 0.026 
Waist circumference (cm)  99.54±1.13 
 
104.16±1.14 0.0011 
SBP (mm of Hg)  129.76±1.15 
 
131.91±1.12 0.23 
DBP (mm of Hg)  81.55±1.12 
 
79.15±1.12 0.016 
Total cholesterol (mg/dl)  187.65±1.26 
 
190.66±1.22 0.49 
Triglycerides (mg/dl)  112.6±1.67 
 
93.04±1.56 0.0003 
HDL-C (mg/dl) 47.14±1.32 
 
53.7±1.28 <.0001 
LDL-C (mg/dl) 109.55±1.51 
 
113.77±1.32 0.32 
FPG (mmol/L)  95.51±1.14 
 
135.42±1.49 <.0001 
A1C (%)  5.89±1.07 
 
7.51±1.22 <.0001 
Insulin 12.37±1.83 
 
16.14±1.95 0.0007 
HOMA2_B 115.48±1.52 
 
70.06±2.22 <.0001 
HOMA2_IR 1.56±1.78 
 
2.14±2.00 <.0001 
HOMA2_IS 64.07±1.77 
 
46.6±2.00 <.0001 
kcal  2235.68±1.41 
 
1993.01±1.47 0.0039 
PA_MET_wk 21.91±4.22 
 
13.45±4.62 0.0075 
Values are unadjusted mean ± SD for continuous variables or N for categorical variables. * 
Derived from t-test for means or chi-square test for percentage differences between cases and 
controls. BMI= body mass index; SBP= systolic blood pressure; DBP= diastolic blood; HDL-
C= high-density lipoprotein cholesterol; LDL-C=low density lipoprotein cholesterol;FPG= 
fasting plasma glucose; A1C= hemoglobin A1C; PA_MET_wk= physical activity  measured by 
metabolic equivalents (MET) per week 
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Table 2. Distribution of allele frequencies and the genotypes of three 
genetic models in our studied population. 
SNPs Number (%) p* values 
rs12255372 
Without T2D  
n (%) 
With T2D  
n (%) 
 
Dominant Model    
GG 74 (43.27) 55 (32.54) 
0.054 
GT+TT 97 (56.73) 114 (67.46) 
Additive Model    
GG 74 (43.02） 55 (32.54) 
0.0005 GT 80 (46.51) 70 (41.42) 
TT 17 (9.88) 44 (26.04) 
Recessive Model    
GG+GT 154 (90.06) 125 (73.96) 
0.0002 
TT 17 (9.88) 44 (26.04) 
Allele Model    
G 228 (66.67) 180 (53.25) 
0.0004 
T 114 (33.33) 158 (46.75) 
rs11196205 
Without T2D  
n (%) 
With T2D  
n (%) 
 
Dominant Model    
CC 60 (34.88) 59 (34.91) 
0.92 
GC+GG 112 (65.12) 110 (65.09) 
Additive Model    
CC 60 (34.88) 59 (34.91) 
0.46 GC 75 (43.60) 82 (48.52) 
GG 37 (21.51) 28 (16.57) 
Recessive Model    
CC+GC 135 (78.49) 141 (83.43) 
0.063 
GG 37 (21.51) 28 (16.57) 
Allele Model    
C 195 (56.69) 200 (59.17) 
0.51 
G 149 (43.31) 138 (40.83) 
rs7903146 
Without T2D  
n (%) 
With T2D  
n (%) 
 
Dominant Model    
CC 76 (44.19) 58 (34.32) 
0.079 
CT+TT 96 (55.81) 111 (65.68) 
Additive Model    
CC 76 (44.19) 58 (34.32) 
0.018 
CT 73 (42.44) 69 (40.83) 
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TT 23 (13.37) 42 (24.85) 
Recessive Model    
CC+CT 149 (86.63) 127 (75.15) 
0.010 
TT 23 (13.37) 42 (24.85) 
Allele Model    
C 225 (64.84) 185 (54.73) 
0.0044 
T 119 (35.16) 153 (45.27) 
rs7901695 
Without T2D  
n (%) 
With T2D  
n (%) 
 
Dominant Model    
TT 68 (39.53) 55 (32.54) 
0.22 
TC+CC 104 (60.47) 114 (67.46) 
Additive Model    
TT 68 (39.53) 55 (32.54) 
0.028 TC 75 (43.60) 65 (38.46) 
CC 29 (16.86) 49 (28.99) 
Recessive Model    
TT+TC 143 (83.14) 120 (71.01) 
0.011 
CC 29 (16.86) 49 (28.99) 
Allele Model    
T 211 (61.34) 175 (51.78) 
0.012 
C 133 (38.66) 163 (48.22) 
rs7895340 
Without T2D  
n (%) 
With T2D  
n (%) 
 
Dominant Model    
AA 58 (33.72) 56 (33.14) 
0.91 
GA+GG 114 (66.28) 113 (66.86) 
Additive Model    
AA 58 (33.72) 56 (33.14) 
0.18 GA 73 (42.44) 85 (50.30) 
GG 41 (23.84) 28 (16.57) 
Recessive Model    
AA+GA 131 (76.16) 141 (83.43 
0.12 
GG 41 (23.84) 28 (16.57) 
Allele Model    
A 189 (54.94) 197 (58.28) 
0.38 
G 155(45.06) 141(41.72) 
rs4506565 
Without T2D  
n (%) 
With T2D  
n (%) 
 
Dominant Model    
AA 69 (40.12) 54 (31.95) 
0.14 
AT+TT 103 (59.88) 115 (68.05) 
Additive Model    
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AA 69 (40.12) 54 (31.95) 
0.025 AT 74 (43.02) 66 (39.05) 
TT 29 (16.86) 49 (28.99) 
Recessive Model    
AA+AT 143 (83.14) 120 (71.01) 
0.011 
TT 29 (16.86) 49 (28.99) 
Allele Model    
A 212 (61.63) 174 (51.48) 
0.0075 
T 132 (38.37) 164 (48.52) 
 
* Derived from chi-square test. 
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Table 3. Unconditional logistic regression with/without adjustment by covariates in three 
genetic models 
rs12255372 
Unadjusted OR 
(95% CI) 
p* values 
Adjusted OR 
(95% CI) 
p& values 
Dominant Model     
GG Ref 0.042 reference 0.040 
GT+TT 1.58 (1.02~2.46)  1.61 (1.02~2.54)  
Additive Model     
GG reference 0.0007 reference 0.0026 
GT 1.18 (0.73~1.89)  1.24 (0.76~2.02)  
TT 3.48 (1.80~6.74)  3.24 (1.65~6.36)  
Recessive Model     
GG+GT reference 0.0002 reference 0.0008 
TT 3.19 (1.74~5.85)  2.88 (1.55~5.3)  
rs7903146 
Unadjusted OR 
(95% CI) 
p* values 
Adjusted OR 
(95% CI) 
p& values 
Dominant Model     
CC reference 0.063 reference 0.031 
CT+TT 1.52 (0.98~2.35)  1.65 (1.05~2.6)  
Additive Model     
CC reference 0.020 reference 0.014 
CT 1.24 (0.77~1.99)  1.35 (0.83~2.21)  
TT 2.39 (1.30~4.42)  2.57 (1.37~4.84)  
Recessive Model     
CC+CT reference 0.0078 reference 0.0076 
TT 2.14 (1.22~3.75)  2.19 (1.23~3.9)  
rs7901695 
Unadjusted OR 
(95% CI) 
p* values 
Adjusted OR 
(95% CI) 
p& values 
Dominant Model     
TT reference 0.18 reference 0.11 
TC+CC 1.36 (0.87~2.11)  1.46 (0.92~2.31)  
Additive Model     
TT reference 0.029 reference 0.018 
TC 1.07 (0.66~1.74)  1.14 (0.69~1.89)  
CC 2.09 (1.17~3.73)  2.31 (1.26~4.22)  
Recessive Model     
TT+TC reference 0.0083 reference 0.0052 
CC 2.01 (1.2~3.39)  2.15 (1.26~3.68)  
rs4506565 
Unadjusted OR 
(95% CI) 
p* values 
Adjusted OR   
(95% CI) 
p& values 
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Dominant Model     
AA reference 0.12 reference 0.069 
AT+TT 1.43 (0.92~2.23)  1.53 (0.97~2.44)  
Additive Model     
AA reference 0.027 reference 0.016 
AT 1.14 (0.70~1.85)  1.21 (0.73~2.00)  
TT 2.16 (1.21~3.86)  2.38 (1.3~4.36)  
Recessive Model     
AA+AT reference 0.0083 reference 0.0052 
TT 2.01 (1.2~3.39)  2.15 (1.26~3.68)  
*P value and Odds ratios (OR) with 95% confidence interval (CI) were calculated using unconditional 
logistic models, and &further adjusted by BMI, gender, age, physical activity and calorie intake. 
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Table 4. Comparison of T2D related metabolic traits between non-risk allele 
carriers and risk allele carriers of SNPs rs7903146, rs7901695 and rs4506565 
in non-diabetic controls. 
rs7903146 CC (N=76) CT/TT (N=96) p* values 
BMI (kg/m2) 29.54±1.18 29.61±1.18 0.92 
Waist circumference (cm) 99.47±1.11 99.6±1.14 0.94 
SBP (mm of Hg) 128.56±1.15 130.71±1.14 0.43 
DBP (mm of Hg) 81.82±1.13 81.33±1.11 0.73 
Total cholesterol (mg/dl) 187.75±1.26 187.58±1.25 0.98 
Triglycerides (mg/dl) 114.02±1.69 111.5±1.65 0.78 
HDL-C (mg/dl) 47.14±1.33 47.14±1.31 1.00 
LDL-C (mg/dl) 107.93±1.59 110.83±1.45 0.68 
FPG (mmol/L) 93±1.16 97.48±1.12 0.019 
A1C (%) 5.82±1.07 5.93±1.07 0.069 
Insulin 12.07±1.78 12.61±1.87 0.66 
HOMA2_B 119.15±1.53 112.77±1.5 0.41 
HOMA2_IR 1.48±1.71 1.63±1.82 0.30 
HOMA2_IS 67.41±1.7 61.55±1.81 0.32 
rs7901695 TT (N=68) TC/CC (N=104) p* values 
BMI (kg/m2) 29.38±1.18 29.71±1.18 0.67 
Waist circumference (cm) 99.2±1.11 99.77±1.14 0.76 
SBP (mm of Hg) 127.98±1.15 130.93±1.15 0.28 
DBP (mm of Hg) 81.13±1.13 81.82±1.11 0.62 
Total cholesterol (mg/dl) 188.56±1.26 187.07±1.25 0.83 
Triglycerides (mg/dl) 111.52±1.66 113.3±1.67 0.84 
HDL-C (mg/dl) 48.17±1.33 46.49±1.31 0.42 
LDL-C (mg/dl) 107.97±1.62 110.58±1.44 0.71 
FPG (mmol/L) 92.62±1.16 97.42±1.12 0.013 
A1C (%) 5.82±1.07 5.93±1.07 0.067 
Insulin 11.75±1.81 12.79±1.84 0.41 
HOMA2_B 118.42±1.56 113.67±1.48 0.54 
HOMA2_IR 1.45±1.72 1.65±1.8 0.16 
HOMA2_IS 69.09±1.72 60.97±1.79 0.18 
rs4506565 AA (N=69) AT/TT (N=103) p* values 
BMI (kg/m2) 29.33±1.18 29.75±1.18 0.58 
Waist circumference (cm) 99.27±1.11 99.73±1.14 0.79 
SBP (mm of Hg) 127.78±1.14 131.1±1.15 0.23 
DBP (mm of Hg) 81.15±1.13 81.81±1.11 0.63 
Total cholesterol (mg/dl) 189.05±1.26 186.74±1.25 0.73 
Triglycerides (mg/dl) 113.53±1.69 111.99±1.66 0.86 
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HDL-C (mg/dl) 47.86±1.33 46.67±1.31 0.56 
LDL-C (mg/dl) 108.13±1.61 110.5±1.44 0.74 
FPG (mmol/L) 92.61±1.16 97.48±1.12 0.011 
A1C (%) 5.82±1.07 5.93±1.07 0.089 
Insulin 11.79±1.8 12.77±1.85 0.43 
HOMA2_B 118.75±1.56 113.41±1.48 0.49 
HOMA2_IR 1.45±1.72 1.64±1.8 0.18 
HOMA2_IS 68.8±1.71 61.06±1.8 0.19 
 Values are unadjusted mean ± SD for continuous variables or N for categorical variables. 
* From t-test. P<0.05 considered significant. BMI= body mass index; SBP= systolic blood pressure; 
DBP= diastolic blood; HDL-C= high-density lipoprotein cholesterol; LDL-C=low density 
lipoprotein cholesterol; FPG= fasting plasma glucose; A1C= hemoglobin A1C; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Figure 1. Haploview plot showing linkage disequilibrium (LD) with r2 values and block structure 
for six selected SNPs of TCF7L2 gene.  
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CHAPTER III   INTERACTION BETWEEN TCF7L2 POLYMORPHISM AND 
GLYCEMIC LOAD, DIETARY CARBOHYDRATE AND FIBER INTAKE ON 
THE RISK OF TYPE 2 DIABETES AND ITS ASSOCIATED QUANTITATIVE 
TRAITS IN CUBAN AMERICANS 
Abstract 
Objectives: Type 2 diabetes (T2D) is a multifaceted and chronic metabolic disorder that 
involves complex interaction between environmental factors and genetic predisposition. 
TCF7L2 gene recently emerged as a top candidate gene for T2D. Studies suggested the 
TCF7L2 involvement in incretin hormone regulation, β-cell function, and hepatic glucose 
production. Differences in dietary factors, particularly carbohydrate (CHO) intake that 
influences glycemic regulation, may modify some genetic association with T2D. Few 
studies investigated such interactions in relation to the risk of T2D and none has been 
done in Cuban Americans. We hypothesized that significant interaction exists between 
TCF7L2 common polymorphisms SNP rs7903146 (C>T) and SNP rs7901695 (T>C) in 
TCF7L2 gene and dietary factors in relation to the risk of T2D and related phenotypes in 
Cuban Americans.  
Methods: We genotyped TCF7L2 SNPs rs7903146 and rs7901695 from 341 Cuban 
Americans (169 with and 172 without T2D). Logistic regression method was used to 
assess the association between TCF7L2 SNPs genotypes and the risk of T2D in a 
dominant model. Interaction was tested by including the product of genotype*dietary 
factors in the model. Subgroup analyses were conducted by strata (high vs low) of dietary 
factors including glycemic load (GL), carbohydrate, and dietary fiber intake.  
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Results: We found a significant interaction between dietary fiber intake and SNP 
rs7903146 polymorphism for the risk of T2D (p= 0.044). For subgroup analyses, SNP 
rs7903146 significantly associated with the risk of T2D (odds ratio (OR) = 2.43, p= 
0.010) only for the subgroup of a higher dietary fiber intake, while no significant results 
were found for the subgroup with a lower dietary fiber intake. For SNP rs7901695, 
significant interaction was also found for fiber intake (p=0.014) as well as glycemic load 
(p=0.040). Similarly, significant associations were only found within higher intake 
groups of higher fiber (OR=2.45, p=0.011) and GL (OR=2.18, p=0.037) for SNP 
rs7901695. Additionally, consistent results were found for T2D related quantitative traits 
for both SNPs in control subjects. For SNP rs7903146, risk allele carriers had significant 
higher levels of A1C% compared to non-risk allele carriers in all higher intake groups. 
For SNP rs7901695, risk allele carriers had significantly higher means of A1C%, 
HOMA2_IR (homeostatic model assessment of insulin resistance) and ghrelin and 
significantly lower means of HOMA2_IS (homeostatic model assessment of insulin 
sensitivity) for all three higher intake groups. For lower intake groups of CHO and GL, 
compared to non-risk allele carriers, risk allele carriers for both SNPs had significant 
higher level of fasting blood glucose and significantly lower level of HOMA2_B 
(homeostatic model assessment of β-cell function). 
Conclusions: Carbohydrate quality and quantity, and fiber content of the diet could 
modify the risk of T2D associated with TCF7L2 SNPs rs7903146 and rs7901695 in 
Cuban Americans. Higher ORs for developing T2D was observed for risk allele carriers 
of both SNPs when reporting higher intake of CHO, dietary fiber or GL. Investigation of 
the mechanisms through which TCF7L2 SNPs-diet interactions affect the risk of T2D 
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might yield new insights into the understanding of etiology of diabetes and have 
implications for prevention of T2D in individuals carrying TCF7L2 risk allele(s) though 
dietary modification. 
Introduction 
Diabetes is a complex, multi-factorial metabolic disorder characterized by a 
relative deficiency in insulin action, characterized by hyperglycemia due to insulin 
resistance or diminished capacity by the pancreas to produce insulin [1]. Currently, 
diabetes is the fastest-growing epidemic and the International Diabetes Federation 
estimated that 425 million people live with diabetes in 2017 and this number is projected 
rise to 629 million by 2045 [2]. Type 2 Diabetes (T2D) is the most prevalent form, 
accounting for approximately 90% to 95% of all diagnosed cases and currently ranks 
seventh among the leading causes of death in the United States [3]. Heritability of T2D 
was estimated to be between 30% and 80% based on twin and familial studies [4-8]. High 
throughput genome-wide association studies (GWAS) have identified a number of 
variants associated with the risk of T2D but most reported variants have small to 
moderate effects for the development of T2D [9]. Some investigators speculated that the 
genetic predisposition to T2D would work synergically with the environmental 
facilitators, such as poor dietary, inactivity and obesity, to contribute to the development 
of T2D but few studies have been conducted in the area of interaction between these two 
[1].  
TCF7L2 has emerged as one of the top candidate genes for T2D in the past decade 
since its first discovery by Decode group [10]. The TCF7L2 gene product is a high-
mobility box-containing group (HMG) transcription factor which is a ubiquitous protein 
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that belongs to a family of TCF/lymphoid enhancer factor [11]. Studies suggested 
TCF7L2 plays an important role in glucose homeostasis via regulation of the production 
of incretin hormone, β-cell functions and hepatic glucose production via Wnt signal 
pathway [12-14]. Insulin is secreted in response to elevated postprandial blood glucose 
that is directly linked to the quantity and quality of intake of carbohydrate, which could 
be mathematically determined by food's glycemic load. On the other hand, dietary fiber is 
an important factor to influence postprandial glucose response via slowing down or 
reducing the absorption of glucose [15]. It is biologically possible that dietary 
carbohydrate intake with different glycemic loads and fiber contents may modify the 
association between risk-conferring SNPs in TCF7L2 gene and the risk of T2D. Several 
previous studies have demonstrated such modification effect of food-gene interaction on 
the risk of T2D [16-19].  
Association of TCF7L2 SNPs with the risk of T2D have been replicated in several 
populations. However, inconsistent replication of results is often present when studying 
genetic associations, possibly due to the ethnic diversity at the complex interplay between 
genetic and environmental factors. In the United States, Hispanics are often grouped 
together for research purpose, though many ethnicities exist within the Hispanic 
population and studies have demonstrated ethnic variations in many aspects such as 
disease mortality, health outcomes, behaviors, risk factors, demographics, and social 
determinants within Hispanic populations [20]. Among Hispanic population, Cuban 
Americans represent the third largest minority group in the United States and also have 
the highest proportion of the elderly population (26% for age 55 or older) compared to 
other Hispanic groups (11.9% for Mexicans and 16.1% for Puerto Rican) [21]. Although 
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Cuban Americans (9.0%) have a lower prevalence of T2D than Mexicans (13.8%) and 
Puerto Ricans (12.0%) but still 1.22 times higher than non-Hispanic whites (7.4 %) and a 
highest proportion of diabetes as the underlying cause of death (44%) as compared to 
other Hispanic groups (39% for Puerto Ricans and 37% for Mexican Americans [22, 23].  
By far, existing studies have examined genetic association with T2D in Hispanic 
subgroup, of which majority were carried on populations of Mexican origin [24-26]. The 
disproportionally affected rates of T2D in Cuban Americans could be ascribed to 
increased genetic predisposition and its interaction with acculturation related unhealthy 
diet behavior (e.g. higher sugar and low fiber) but few studies have addressed this area 
[27].  In the present study, we hypothesized that there is a gene-diet interaction between 
different dietary intakes, particularly glycemic load (GL), carbohydrate (CHO) and fiber 
intakes, and variants in TCF7L2 gene in incident type 2 diabetes.  
Methodology 
Subjects 
This was a case-control study. The target population was Cuban American adults 
in Broward and Miami-Dade Counties, Florida. Approximately half of the participants 
had type 2 diabetes and the rest were free of diabetes. Participants were initially recruited 
from randomly generated mailing lists. The lists of addresses were purchased from 
Knowledge Base Marketing, Inc., Richardson, TX, U.S. Throughout a one-year period, 
ten thousand letters, along with an invitation flyer in both English and Spanish, were 
mailed to Cuban Americans. Of the participants who received letters, 4% (n = 388) 
responded. Interested participants were interviewed on the phone. The study purpose was 
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explained and preliminary demographics (age, sex and ethnicity) of the respondents were 
recorded to determine eligibility.  
To ascertain T2D status, each participant was asked for the age of diagnosis and 
initial treatment modalities. Only 18 out of 388 subjects did not qualify for the study: for 
not being Cuban Americans (n= 2), age younger than 30 years (n= 9), and having other 
chronic illnesses (n=7). If a subject was determined to be eligible, then their participation 
was requested at the Human Nutrition Laboratory at Florida International University 
(FIU). Validated questionnaires were used to collect information on demographics and 
physical activities [28]. Participants were instructed to refrain from smoking, consuming 
any food and beverages except water, and doing any unusual exercise for at least 8 hours 
prior to their blood collection. Subjects with T2D were matched for age and gender with 
subjects without diabetes. This study was approved by the Institutional Review Board at 
FIU. The purpose and protocol of the study were explained to the subjects, and their 
written consent, either in Spanish or English, was obtained prior to the commencement of 
the study. Seven participants reported not having diabetes but were reclassified because 
their lab results classified them as having T2D according to American Diabetes 
Association (ADA) standards. These subjects were given their laboratory results and 
referred to their physicians. For the data analysis, subjects with missing genotyping 
information were excluded from analysis. In total, we included data from subjects with 
(n=172) and without (n=169) T2D who were 30 years and older. 
Anthropometric measurements and medical assessment 
A SECA balance scale was used to measure both height and weight (Seca Corp, 
US) which were later used to calculate body mass index (BMI) in kg/height in m2. 
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Additionally, waist circumference (WC) to the nearest 0.1 cm was measured horizontally 
with a non-stretchable measuring tape placed midway between the 12th rib and iliac crest 
at minimal respiration and was used to determine central obesity (male=102 cm/ 
female=88 cm). Blood pressure (BP) measurement was repeated two times then averaged 
using a random zero sphygmomanometer (Tycos 5090-02 Welch Allyn Pocket Aneroid 
Sphygmomanometer, Arden, NC, USA) and a stethoscope (Littmann Cardiology, 3M, St 
Paul, MN, USA) in participants after a 15-minute rest while sitting. Presence of 
hypertension was established either systolic BP ≥ 140 mm Hg, diastolic BP ≥ 90 mm Hg 
or they were using antihypertensive medication.  
Assessment of dietary intake 
Dietary intake was determined using the semi-quantitative food frequency 
questionnaire (FFQ; 97GP 2006 version copyrighted at Harvard University, Boston, MA, 
U.S.), developed by Walter C. Willett, which has been validated by Nath and Huffman for 
Cuban Americans [29, 30]. On the FFQ, participants self-report average consumption of 
specified amounts of various foods and vitamins over the past year. Daily servings for 
food groups were calculated by summing frequency factors for all related food items. 
Macronutrient intakes were calculated by multiplying frequency of consumption by the 
nutrient value of the food item obtained from the Harvard University Food Composition 
Database. The Glycemic Load (GL) was calculated by multiplying the CHO content of 
one serving by the glycemic index value of the food and beverage. We then multiplied 
this GL value by the frequency of consumption and summed the products of all food and 
beverage items to produce the dietary GL.  
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Biospecimen analyses 
Data for serum biomarkers were available from our parental database. Briefly, 
twenty ml of venous blood was collected from each participant after an overnight fast (at 
least 8 hours) by a certified phlebotomist. Glucose levels in serum were quantified using 
hexokinase method. Whole blood was used to measure A1C using Roche Tina Quant 
method (Laboratory Corporation of America, Lab Corp, FL, U.S.). Automatic chemical 
analyzer was employed to determine high-density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (TC). 
Serum insulin levels were determined using the Human Insulin ELISA kit from Millipore 
(St Charles, MZ, U.S.). The level of acylated ghrelin was assayed with fasted blood 
plasma by Enzyme Immunometric Assay (Cayman Chemical Inc., MI, US). The 
manufacturer’s protocol was followed to perform this Sandwich ELISA assay.  
Determination of beta cell function (HOMA2-β), insulin resistance (HOMA2-IR), and 
insulin sensitivity (HOMA2-IS) 
HOMA2 (Homeostatic model assessment 2) is based on the Oxford University 
HOMA2 calculator (www.ocdem.ox.ac.uk) [31] and is used to estimate beta cell function 
(HOMA2-β), insulin resistance (HOMA2-IR), and insulin sensitivity (HOMA2-IS). The 
HOMA2 computer model accounts for variations in hepatic and peripheral glucose 
resistance (Rudenski, Matthews, Levy, & Turner, 1991). The computer model can be used 
to determine β-cell function (%B) insulin sensitivity (%S), and the insulin resistance 
index from paired fasting plasma glucose and radioimmunoassay insulin across a range of 
1-2,200 pmol/l for insulin, and 1-25 mmol/l for glucose [31].  
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Isolation of DNA and Genotyping 
Genomic DNA was isolated from the whole blood using QIAamp DNA Blood mini 
kit (Qiagen, Hilden, Germany), according to the vender’s recommended protocol. Quality 
and quantity of the isolated DNA was assessed by using 2000c nanodrop 
spectrophotometer (Thermo Scientific, USA). Genotyping for all six SNPs was 
performed by real-time PCR amplification on BioRad CFX96 real time PCR instrument 
(Hercules, CA, USA) using commercially available TaqMan allelic discrimination assays 
(LifeTech, Foster City, CA, USA). To ensure reproducibility and reliability of genotyping 
method, 10% of the DNA samples was duplicated during genotyping. We obtained a 
100% concordance between the genotyped duplicate samples for the single nucleotide 
polymorphism (SNP).  
Statistical Analysis 
Statistical analysis was conducted using SAS version 9.4 (SAS Institute Inc., Cary, 
NC).  All statistical tests were two-tailed, and the threshold for statistical significance was 
set at P≤0.05. Genotype counts in each SNP was checked for Hardy-Weinberg 
equilibrium (HWE) in controls using the Chi-squared goodness-fit test. The distributions 
of the T2D related quantitative traits, such as HOMA2 indexes, BMI, WC, et al, were 
markedly skewed, which were normalized, to a large extent, by their logarithmic 
transformation. Therefore, formal statistical tests on continuous values of these 
quantitative traits were performed on logarithmically transformed values. Demographic 
and clinical information between cases and controls was compared using student’s t-test 
for continuous variables, and Chi-squared test for categorical variables. All genetic 
associations were assessed by using the dominant genetic model (noncarrier=0, 
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heterozygous and homozygous=1). Unconditional logistic regression models were used 
to calculate odds ratios (OR) and 95% confidence intervals (CIs) to assess the 
relationship of all SNPs with binary outcome for case-control status (T2D=Yes/No). 
Dietary factors including CHO intake, dietary fiber intake and glycemic load were 
dichotomously divided by median values. Gene-diet interactions on the risk of T2D was 
tested by including the product of genotype*dietary factor in the logistic model. Study 
subjects were further divided into two groups by strata of dietary factors. Within each 
category of dietary factors, logistic regression models were utilized to calculate odds 
ratios (OR) and 95% confidence intervals (CIs), adjusted for potential confounding 
factors such as age, sex, BMI, physical activities and calorie intake. To evaluate the 
relationship between SNPs and T2D related quantitative traits, the student’s t-test 
methods was used again to compare the mean levels of T2D related quantitative traits 
such as age, sex, BMI, physical activities and calorie intake between risk allele carriers 
and non-carriers in control subjects, stratified by dietary factors. Quanto 
(http://biostats.usc.edu/Quanto.html) was used to calculate the statistical power for the 
gene-diet interaction with incident T2D. Assuming an OR of 0.90 for higher fiber intake 
and an OR of 1.5 for TCF7L2 risk-conferring genotype (0.30 allele frequency, dominant 
model) on T2D incidence, at significant level of 0.05 (two sides), we had 80% power to 
detect an interaction of OR of at least 2.4 in T2D incidence.  
Results 
This study included N=341 Cuban Americans (n=222 female and n=119 male) with 
(n=172) and without (n=169) T2D. Characteristics of the participants were presented as 
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comparison of means ±SE by diabetes status (Table 1). The mean of age among 
participants without diabetes was 62.98±0.83 and 65.05±0.92 for participants with 
diabetes; where the majority were female in both groups. Compared to adults without 
diabetes, adults with diabetes had significantly higher means of BMI, WC, fasting plasma 
glucose, A1C (%), insulin, and HOMA2_IR, and significantly lower HOMA2_B, 
HOMA2_IS, CHO, GL and calorie intake.  
Table 2 and Table 3 shows the interactions of TCF7L2 SNP rs7903146 and 
rs7901695 with carbohydrate, fiber and GI intake on the risk T2D and results from 
logistic regression for all subjects and stratified by dietary factors, respectively. Overall, 
the risk-conferring genotype of SNP rs7903146 was significantly associated with the risk 
of T2D with the dominant model. Compared to non-risk allele carriers as reference, the 
adjusted odds ratio (OR) for risk allele carriers is 1.65 (CI: 1.05-2.60, p=0.031). A 
significant interaction was also found between dietary fiber intake and SNP rs7903146 
polymorphism in relation to the risk of T2D (p= 0.044). For subgroup analysis by strata 
of dietary fiber, SNP rs7903146 (OR = 2.43, p = 0.010) was significantly associated with 
the risk of T2D only for the subgroup of a higher dietary fiber intake (dietary fiber intake 
≥ median), while no significant result was found for the subgroup with a lower dietary 
fiber intake. Similar trends were also found when conducting subgroup analysis by strata 
of CHO and GL for SNP rs7903146. For SNP rs7901695, no significant association were 
found in relation to the risk of T2D in all subjects (p=0.11) by the dominant model. After 
including the gene X diet interaction term in the model, significant interaction was found 
for fiber intake (p=0.014) and glycemic load (p=0.040). In accordance to SNP rs7903146, 
significant results were only found within higher intake groups. In higher fiber intake 
68 
 
group and higher GL group, compared to non-risk carriers, the multi-variable adjusted 
OR for risk allele carriers were 2.45 (CI: 1.23-4.90, p=0.011) and 2.18 (CI: 1.05-4.54, 
p=0.037), respectively. 
Table 4 and table 5 shows T2D related metabolic traits between non-risk allele 
carriers and risks allele carrier of SNPs rs7903146 and rs7901695 by strata of dietary 
factors in controls, respectively. Consistent results were found for higher intake groups of 
dietary factors for both SNPs. For SNP rs7903146, risk allele (T) carriers has significant 
higher levels of A1C% compared to non-risk allele carriers in all higher intake groups. 
For SNP rs7901695, risk allele (C) carriers had significantly higher means of A1C%, 
HOMA2_IR and ghrelin and significantly lower means of HOMA2_IS than non-risk 
allele carriers in all three higher intake groups. For lower intake groups of CHO and GL, 
compared to non-risk allele carriers, risk allele carriers for both SNPs has significant 
higher level of fasting blood glucose and significantly lower level of HOMA2_B. In 
addition, we found in our studied population, the investigated three dietary variables are 
highly correlated with each other, the Pearson correlation coefficient between each two 
dietary factors are 0.99 (p<0.0001) for CHO intake and GL, 0.74 (p<0.0001) for CHO 
intake and dietary fiber intake, and 0.66 (p<0.0001) for dietary fiber intake and GL. 
Similar trends found across the dietary factors could be partially due to the significant 
correlation amongst them. 
Discussion 
SNPs in the TCF7L2 gene has the largest effect among the various susceptibility 
genes on type 2 diabetes and have been widely replicated associated with T2D [32]. In 
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addition, several studies revealed that variation in TCF7L2 are associated with several 
glucose homeostasis related phenotypes such as impaired insulin secretion and incretin 
effects, reduced GLP-1-induced insulin, beta cell function, insulin sensitivity and 
resistance, and hepatic glucose production [33-35]. Considering insulin is regulated in 
response to the variation of blood glucose level and secretion of incretin hormones may 
vary by dosage of carbohydrates [36], dietary carbohydrate might modify the association 
between TCF7L2 SNPs and the risk of T2D. In the present study, we found significant 
interactions between two TCF7L2 SNPs (rs7903146 and rs7901695), dietary fiber and 
glycemic load in relation to the risk of T2D in Cuban Americans. Subgroup analysis by 
strata of dietary factors revealed that the increased risks were only significant among 
higher intake participants, compared to participants who reported lower intake of dietary 
factors. 
Polymorphism rs7903146 is the most studied SNP in TCF7L2 gene. Repeated 
replications of association with this SNP in relation to the risk of T2D have been reported 
in several populations, including Hispanic population [37]. Consistent with previous 
findings, our research replicated the association in Cuban Americans. Importantly, we 
also identified a significant interaction between this SNP and the dietary fiber intake 
(p=0.044) on the risk of T2D. The odds ratio increased from 1.65 (CI:1.05-2.60, p=0.031) 
for all subjects to 2.43 (CI:1.24-4.79, p=0.010) when analysis was conducted in the 
subgroup of higher fiber intake. Our result was in accordance with a previous study.  
Hindy et al. performed an investigation on a cohort of nearly 25,000 initially nondiabetic 
Swedish adults to assess interactions between dietary fiber and the TCF7L2 rs7903146 
variant on T2D incidence [18]. The authors reported the elevated risk of T2D with 
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rs7903146 increased with higher intake of dietary fiber. Two other studies also found 
significant interactions between whole grain intake and rs7903146 on the risk of T2D 
[15, 38]. Both studies demonstrated that the protective effect from whole grain intake 
against the development of T2D was negated by the risk T allele of rs7903146. Higher 
fiber intake has been associated with increased plasma short-chain fatty acids (SCFAs), 
which are byproduct of fiber fermentation in large intestine. It has been demonstrated that 
SCFAs can stimulate incretin hormone secretion from L-cells via G-protein-coupled 
receptor FFAR2 [39]. Thus, it could be speculated that risk allele carriers of rs7903146 
have decreased protective effect from SCFAs induced incretin hormone secretion as 
rs7903146 has been previously reported with impaired incretin response [40, 41].  
Though the interaction was not statistically significant between rs7903146 and the other 
two dietary factors (CHO intake, GL) for the risk of T2D, similar trend were identified 
when analysis by strata of these two dietary factors were conducted. For both dietary 
factors, the odds ratio for the risk of T2D increased from lower intake groups (OR=1.26, 
p=0.50 for CHO intake; OR=1.27, p=0.49 for GL) to higher intake groups (OR=2.08, 
p=0.040 for CHO intake; OR=2.08, p=0.041for GL). Findings from the present study 
were similar as a previous report from Nurses' Health Study. Researchers found a 
significant interaction between GL and a variant (rs12255373) in TCF7L2 gene on the 
risk of T2D and the risk allele was reported to have a stronger association with type 2 
diabetes among individuals with higher dietary glycemic load and glycemic index [19].  
In the present study, we also found that in controls, risk allele carriers of rs7903146 had 
significantly higher A1C% level when reporting a higher intake of carbohydrate or GL. 
These results tentatively suggested that the risk T allele of rs7903146 might affect 
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specific metabolic processes to make an individual more susceptible to the harmful 
effects of environmental factors such as high consumption of carbohydrate dense food, as 
previous studies on the underlying mechanism demonstrated subjects with risk TCF7L2 
genotype exhibited substantially reduced insulin response to glucose, impairing β-Cell 
function and hepatic glucose production [35, 42]. In contrast to higher intake group of 
CHO or GL, in lower intake group of controls, significantly lower beta cell (HOMA2-B) 
founds were found in risk allele carriers of both studied SNPs, compared to non-risk 
allele carriers. It is biologically possible that deficit within genes might be more 
manifesting under the condition that the compensatory mechanism for the regulation of 
high blood glucose level hasn’t get involved yet. Further investigation need to be 
performed to confirm this finding. 
SNP rs7901695 is another most investigated SNP on TCF7L2 gene. Significant 
associations were not only found between this SNP and the risk of T2D, recent studies 
also demonstrated significant associations with gestational and type 1 diabetes [26, 43]. 
In accordance with previous findings, our research replicated the association between 
rs7901695 and the risk of T2D in Cuban Americans. Consistent with the finding for 
rs7903146, a similar significant interaction with dietary fiber intake (p=0.014) was found 
for rs7901695, as well as the interactions with GL (p=0.040). To our best knowledge, this 
is the first report on the significant interactions between SNP rs7901695 and dietary 
factors on the risk of T2D. Results of logistic regression by strata of dietary factors (GL 
and dietary fiber intake) showed that ORs of developing T2D in relation to the risk 
genotype of rs7901695 substantially increased from lower intake group (OR=0.92, 
p=0.80 for fiber intake; OR=0.97, p=0.93 for GL) to higher intake group with significant 
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results only found in higher intake groups (OR=2.45, p=0.011 for fiber intake; OR=2.18, 
p=0.037 for GL). For the T2D related quantitative traits in control subjects, in addition to 
the finding that significantly higher A1C% level was found in risk allele carriers than that 
in non-carriers within higher intake groups of three dietary factors, HOMA2-IR and 
HOMA2_IS were also significantly different between risk allele carriers and non-carriers 
with HOMA2-IR significantly higher and HOMA2_IS significantly lower for risk allele 
carriers. HOMA model was recognized as robust clinical and epidemiological tool in 
descriptions of the pathophysiology of beta cell functions and insulin sensitivity [31]. Our 
results can roborate the findings from previous studies. An earlier investigation 
demonstrated that rs7901695 were significantly associated with insulin sensitivity by 
intravenous glucose tolerance tests in non-diabetic subjects [44]. A recent functional 
study also revealed the involvement of TCF7L2 gene in whole-body glucose intolerance 
and hepatic insulin resistance [27]. Collectively, those evidence suggested the 
involvement of TCF7L2 rs7901695, or SNPs in the adjacent region in the linkage 
disequilibrium with rs7901695, in the pathology of T2D in Cuban Americans, especially 
for people who has higher intake of CHO and/or dietary fiber. 
Another novel finding from the present study is the significant difference on acylated 
ghrelin levels between rs7901695 risk allele carriers and non-risk allele carriers in 
controls when reporting higher intake of CHO, dietary fiber or GL. Similar trends was 
also found for rs7903146 but didn’t reach significance. Ghrelin, also known as “the 
hunger hormone”, was recognized as orexigenic hormone to stimulate food intake. The 
main site for ghrelin secretion is in stomach and pancreas, and to a lesser extent in the 
hypothalamus [45]. Previous studies by animal models and in vitro indicated ghrelin 
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plays an important role in glucose homeostasis via negatively influencing insulin 
secretion and insulin sensitivity in peripheral tissues but the mechanism between ghrelin 
and insulin resistance varied within humans [46-48]. Two more recent studies provided 
new insights regarding the role of ghrelin in incretin hormone secretion. Both studies 
suggested ghrelin could be a potential positive regulator for GLP-1 secretion [49, 50]. 
The present study found significantly higher ghrelin level in risk allele carriers of 
rs7901695, compared to non-risk allele carriers in controls of higher intake group of 
dietary factors. Considering accumulated evidence suggesting the involvement of 
TCF7L2 in mediating function of the incretin hormones, the higher ghrelin level found in 
risk allele carriers could be the compensatory mechanism for people with defective 
incretin effects [13, 51, 52].  Further study on the crosstalk between incretins and ghrelin 
need to be further investigated. 
Several limitations need to be considered when interpreting the results from the 
present study. Due to the relatively small sample size, the present study may not have 
enough statistical power to detect the significant interaction. To maximize the sample size 
within each category of dietary factors and genotype, dichotomy for dietary factors and 
dominant model was selected for the present study. Another limitation is the validity of 
dietary variable. Dietary intake was self-reported, it is possible that dietary intake may be 
over or underestimated. Food frequency questionnaires are not optimal for absolute 
intake but can provide population estimates and trend. The FFQ used in the present study 
has been previously validated in this population [53]. Finally, due to the nature of case-
control study, the present study cannot provide information on causality. We acknowledge 
that our data on gene-diet interaction are preliminary and replication is required to 
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conform our findings. Our study also has some significant strengths. This is the first 
study to investigate the gene-diet interaction in Cuban Americans. Both cases and 
controls from the present study were selected from the same population pool and 
geographic area and over 95% of our participants were white Cuban Americans. 
Together, these make our sample a relatively homogenous in terms of genetic, life style 
factors and diet, which consequently reduced the possibility of gene admixture with other 
ethnicities and the false positive rate due to population stratification [54].  
Conclusion 
In conclusion, carbohydrate quality and quantity, and fiber content of the diet could 
modify the risk of T2D associated with TCF7L2 SNPs rs7903146 and rs7901695 in 
Cuban Americans. Higher ORs for developing T2D was observed for risk allele carriers 
of both SNPs when reporting higher intake of CHO, dietary fiber or GL. Investigation of 
the mechanisms by which TCF7L2 SNPs-diet interactions affect the risk of T2D might 
yield new insights into the understanding of etiology of diabetes and have implications 
for prevention of T2D in individuals carrying TCF7L2 risk allele(s) though dietary 
modification. 
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Table 1. Anthropometric, T2D related quantitative traits and dietary intake in all participants  
 Without T2D 
(n=172) 
 With T2D 
(n=169) 
p* value 
Age (Years) 62.98±0.83 
 
65.05±0.92 0.095 
Female (N (%)) 114 (66.67%)  107 (63.31%) 0.52 
BMI (kg/m2)  29.67±1.01  30.88±1.02 0.025 
WC (cm)  99.63±1.13  104.16±1.14 0.0014 
FPG (mmol/L)  95.58±1.01  135.64±1.03 <.0001 
A1C (%)  5.87±1.01  7.54±1.02 <.0001 
Insulin 12.33±1.05  16.12±1.06 0.0007 
HOMA2_B 115.58±1.51  70.11±1.07 <.0001 
HOMA2_IR 1.57±1.05 
 2.14±1.06 <.0001 
HOMA2_IS 64.07±1.05 
 46.53±1.06 <.0001 
CHO (g/day) 284.29±1.03  225.88±1.03 <.0001 
GL 152.93±1.03  116.75±1.04 <.0001 
Dietary fiber (g/day) 21.12±1.04  19.89±1.04 0.28 
Calories (Kcal/day) 2230.54±1.03  1998.20±1.03 0.0039 
Values are unadjusted mean ± SE for continuous variables or N for categorical variables. 
*Derived from t-test for means or chi-square test for percentage differences between cases and 
controls. BMI= body mass index; WC= waist circumference; FPG= fasting plasma glucose; 
A1C= hemoglobin A1C; CHO= carbohydrate intake(g/day); GL= daily glycemic load. 
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Table 2. Interactions of TCF7L2 SNP rs7903146 with carbohydrate, fiber and GL intake on 
the risk T2D and logistic regression for all subjects and stratified by dietary factors 
TCF7L2 SNP rs7903146 X dietary factors 
 Without T2D  
N (%) 
With T2D  
N (%) 
OR (95% CI) p*  
p& for 
interaction 
All Subjects      
CC 76 (44.19) 58 (34.32) reference 0.031 NA 
CT+TT 96 (55.81) 111 (65.68) 1.65 (1.05-2.60)   
SNP X CHO     0.13 
Low (< Median)     
 
CC 27 (40.30) 40 (38.10) reference 0.50 
CT+TT 40 (59.70) 65 (61.90) 1.26 (0.64-2.46)  
High ( ≥ Median)     
CC 48 (46.60) 18 (28.13) reference 0.04 
CT+TT 55 (53.40) 46 (71.88) 2.08 (1.04-4.18)  
SNP X Fiber     0.044 
Low (< Median)     
 
CC 33 (40.74) 38 (40.86) reference 0.62 
CT+TT 48 (59.26) 55 (59.14)   1.18 (0.61-2.25) 
High ( ≥ Median)     
CC 42 (47.19) 20 (26.32) reference 0.01 
CT+TT 47 (52.81) 56 (73.68) 2.43 (1.24-4.79)  
SNP X GL     0.17 
Low (< Median)     
 
CC 28 (42.42) 41 (38.68) reference 0.49 
CT+TT 38 (57.58) 65 (61.32) 1.27 (0.65-2.45)  
High ( ≥ Median)     
CC 47 (45.19) 17 (26.98) reference 0.041 
CT+TT 57 (54.81) 46 (73.02) 2.08 (1.03-4.20)   
*p value and Odds ratios (OR) with 95% confidence interval (CI) were calculated using unconditional 
logistic models, adjusted by BMI, gender, age, physical activity and calorie intake. &p for interaction 
was calculated by including the product of genotype*diet factor in the unconditional logistic model. 
CHO= carbohydrate intake(g/day); GL= daily glycemic load; 
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Table 3. Interactions of TCF7L2 SNP rs7901695 with carbohydrate, fiber and GL intake on the 
risk T2D and logistic regression for all subjects and stratified by dietary factors 
TCF7L2 SNP rs7901695 X dietary factors 
 Without T2D  
N (%) 
With T2D  
N (%) 
OR (95% CI) p* 
p& for 
interaction 
All Subjects      
TT 68 (39.53) 55 (32.54) reference 0.11 NA 
TC+CC 104 (60.47) 114 (67.46)   1.46 (0.92~2.31)  
SNP X CHO     0.086 
Low (< Median)      
TT 24 (35.82) 39 (37.14) reference 0.85  
TC+CC 43 (64.18) 66 (62.86) 1.07 (0.54-2.10)   
High ( ≥ Median)      
TT 43 (41.75) 16 (25.00) reference 0.086  
TC+CC 60 (58.25) 48 (75.00) 1.87 (0.92-3.83)   
SNP X Fiber     0.014 
Low (< Median)      
TT 28 (34.57) 37 (39.78) reference 0.8  
TC+CC 53 (65.43) 56 (60.22) 0.92 (0.48-1.77)   
High ( ≥ Median)      
TT 39 (43.82) 18 (23.68) reference 0.011  
TC+CC 50 (56.18) 58 (76.32) 2.45 (1.23-4.90)   
SNP X GL     0.040 
Low (< Median)     
 
TT 24 (36.36) 41 (38.68) reference 0.93 
TC+CC 42 (63.64) 65 (61.32) 0.97 (0.49-1.90)  
High ( ≥ Median)     
TT 43 (41.35) 14 (22.22) reference 0.037 
TC+CC 61 (58.65) 49 (77.78) 2.18 (1.05-4.54)   
*p value and Odds ratios (OR) with 95% confidence interval (CI) were calculated using unconditional 
logistic models, adjusted by BMI, gender, age, physical activity and calorie intake. p& for interaction 
was calculated by including the product of genotype*diet factor in the unconditional logistic model. 
CHO= carbohydrate intake(g/day); GL= daily glycemic load; 
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Table 4. Comparison of T2D related metabolic traits between non-risk allele carrier and risk allele carrier of SNP rs7903146 by strata 
of dietary factors in subjects without T2D (controls). 
TCF7L2 rs7903146 
CHO (High ( ≥ 
Median)) 
CC CT+TT p value 
CHO (Low (< 
Median)) 
CC CT+TT p value 
FPG (mmol/L)  94.61±1.02 97.21±1.01 0.27 FPG (mmol/L)  89.60±1.03 98.17±1.02 0.0093 
A1C (%)  5.80±1.01 6.03±1.01 0.0039 A1C (%)  5.85±1.01 5.81±1.01 0.67 
Insulin 11.88±1.09 13.31±1.09 0.40 Insulin 12.39±1.11 11.76±1.10 0.74 
HOMA2_B 111.07±1.06 117.73±1.06 0.94 HOMA2_B 137.02±1.1 106.32±1.07 0.029 
HOMA2_IR 1.73±1.08 1.39±1.08 0.053 HOMA2_IR 1.67±1.11 1.52±1.11 0.56 
HOMA2_IS 71.76±1.08 57.99±1.08 0.058 HOMA2_IS 60.26±1.11 66.10±1.11 0.56 
AG 77.07±1.16 117.74±1.19 0.074 AG 61.42±1.20 67.71±1.21 0.72 
Fiber (High ( ≥ 
Median)) 
CC CT+TT p value 
Fiber (Low (< 
Median)) 
CC CT+TT p value 
FPG (mmol/L)  93.53±1.02 97.89±1.02 0.093 FPG (mmol/L)  91.94±1.03 97.35±1.02 0.062 
A1C (%)  5.82±1.01 5.99±1.01 0.044 A1C (%)  5.81±1.01 5.88±1.01 0.40 
Insulin 11.24±1.09 12.82±1.09 0.33 Insulin 13.19±1.11 12.43±1.10 0.71 
HOMA2_B 110.84±1.06 112.55±1.06 0.85 HOMA2_B 132.52±1.09 112.37±1.07 0.13 
HOMA2_IR 1.36±1.09 1.65±1.08 0.092 HOMA2_IR 1.67±1.11 1.62±1.11 0.83 
HOMA2_IS 73.83±1.09 60.92±1.08 0.093 HOMA2_IS 59.70±1.10 62.05±1.11 0.80 
AG 67.24±1.18 105.95±1.23 0.095 AG 75.36±1.18 81.09±1.18 0.76 
GL (High ( ≥ Median)) CC CT+TT p value GL (Low (< Median)) CC CT+TT p value 
FPG (mmol/L)  94.75±1.02 97.39±1.01 0.26 FPG (mmol/L)  89.56±1.03 97.95±1.02 0.0099 
A1C (%)  5.80±1.01 6.01±1.01 0.0085 A1C (%)  5.84±1.01 5.82±1.01 0.86 
Insulin 11.81±1.81 13.17±1.09 0.41 Insulin 12.50±1.11 11.86±1.11 0.75 
HOMA2_B 110.17±1.06 116.42±1.05 0.49 HOMA2_B 137.84±1.10 107.36±1.07 0.035 
HOMA2_IR 1.38±1.08 1.71±1.08 0.051 HOMA2_IR 1.68±1.11 1.53±1.12 0.57 
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HOMA2_IS 72.32±1.08 58.59±1.08 0.056 HOMA2_IS 59.85±1.11 65.64±1.12 0.57 
AG 75.08±1.16 118.40±1.19 0.055 AG 64.69±1.20 66.00±1.21 0.94 
Values are unadjusted mean ± SE. * Derived from t-test for means. CHO= carbohydrate intake(g/day); GL= daily glycemic load; FPG= fasting plasma 
glucose; A1C= hemoglobin A1C; AG= acylated ghrelin. CHO= carbohydrate intake(g/day); GL= daily glycemic load. 
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Table 5. Comparison of T2D related metabolic traits between non-risk allele carrier and risk allele carrier of SNP rs7901695 by strata of dietary 
factors in subjects without T2D (controls). 
TCF7L2 rs7901695 
CHO (High ( ≥ 
Median)) 
TT TC+CC p value 
CHO (Low (< 
Median)) 
TT TC+CC p value 
FPG (mmol/L)  94.14±1.02 97.33±1.01 0.21 FPG (mmol/L)  89.40±1.03 97.87±1.02 0.011 
A1C (%)  5.80±1.01 6.01±1.01 0.015 A1C (%)  5.81±1.01 5.83±1.01 0.84 
Insulin 11.63±1.1 13.39±1.09 0.30 Insulin 11.95±1.13 12.04±1.10 0.97 
HOMA2_B 109.86±1.07 118.06±1.05 0.38 HOMA2_B 136.92±1.11 107.65±1.07 0.043 
HOMA2_IR 1.34±1.09 1.74±1.08 0.021 HOMA2_IR 1.65±1.12 1.53±1.11 0.65 
HOMA2_IS 74.39±1.09 57.58±1.07 0.024 HOMA2_IS 60.79±1.12 65.50±1.11 0.65 
AG 72.85±1.14 117.08±1.19 0.034 AG 59.38±1.24 68.39±1.19 0.62 
Fiber (High ( ≥ 
Median)) 
TT TC+CC p value 
Fiber (Low (< 
Median)) 
TT TC+CC p value 
FPG (mmol/L)  93.02±1.02 98.03±1.02 0.066 FPG (mmol/L)  91.63±1.03 97.09±1.02 0.10 
A1C (%)  5.80±1.01 6.00±1.01 0.024 A1C (%)  5.81±1.01 5.87±1.01 0.50 
Insulin 11.02±1.1 12.92±1.09 0.24 Insulin 12.82±1.13 12.70±1.09 0.95 
HOMA2_B 110.23±1.07 112.93±1.05 0.77 HOMA2_B 132.66±1.10 113.81±1.06 0.17 
HOMA2_IR 1.32±1.09 1.66±1.08 0.043 HOMA2_IR 1.65±1.12 1.63±1.10 0.95 
HOMA2_IS 75.90±1.09 60.32±1.08 0.045 HOMA2_IS 60.46±1.11 61.48±1.10 0.91 
AG 60.21±1.15 110.93±1.23 0.016 AG 78.23±1.21 78.75±1.16 0.98 
GL (High ( ≥ 
Median)) 
TT TC+CC p value 
GL (Low (< 
Median)) 
TT TC+CC p value 
FPG (mmol/L)  94.1±1.02 97.67±1.01 0.16 FPG (mmol/L)  89.46±1.03 97.38±1.02 0.018 
A1C (%)  5.80±1.01 6.00±1.01 0.012 A1C (%)  5.82±1.01 5.83±1.01 0.96 
Insulin 11.38±1.10 13.30±1.08 0.21 Insulin 12.42±1.13 11.96±1.10 0.82 
HOMA2_B 108.25±1.06 117.44±1.05 0.31 HOMA2_B 140.64±1.11 108.17±1.07 0.031 
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HOMA2_IR 1.31±1.09 1.75±1.07 0.0089 HOMA2_IR 1.72±1.12 1.52±1.11 0.45 
HOMA2_IS 76.07±1.09 57.34±1.07 0.010 HOMA2_IS 58.36±1.12 66.08±1.11 0.46 
AG 72.74±1.14 116.47±1.19 0.035 AG 59.53±1.24 68.88±1.19 0.61 
Values are unadjusted mean ± SE. * Derived from t-test for means. CHO= carbohydrate intake(g/day); GL= daily glycemic load; FPG= fasting plasma glucose; 
A1C= hemoglobin A1C; AG= acylated ghrelin. CHO= carbohydrate intake(g/day); GL= daily glycemic load. 
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CHAPTER IV   VARIANTS IN TCF7L2 IN RELATION TO THE RISK OF TYPE 
2 DIABETES AND RELATED METABOLIC TRAITS: DIFFERENCES AMONG 
POPULATIONS WITH AFRICAN ORIGINS IN SOUTH FLORIDA. 
Abstract 
Objectives: In the United States, Blacks are disproportionately affected by diabetes. 
12.7% of non-Hispanic Blacks aged 18 years or older have diabetes, compared to 7.6% of 
non-Hispanic whites in 2015. To date, TCF7L2 (transcription factor 7-like 2) confers the 
strongest statistical evidence for the association with the risk of type 2 diabetes (T2D). 
However, inconsistent replication of results is often present when studying genetic 
associations in Blacks, partially due to the subgroup heterogeneity within Blacks in the 
context of complex interaction between genetic predisposition and environmental factors. 
The primary purpose of this study was to examine six most studied SNPs in TCF7L2 
gene: rs7903146, rs12255372, rs11196205, rs7901695, rs7895340 and rs4506565 in 
relation to the risk of T2D and related metabolic quantitative traits in individuals with and 
without T2D in adults of African American (AA) and Haitian American (HA) from South 
Florida. 
Methods: We conducted a case-control study with 245 AAs (119 without T2D /126 with 
T2D) and 240 HAs (117 without T2D /123 with T2D) and. Unconditional logistic 
regression method was used to assess the association between six TCF7L2 
polymorphisms and the risk of T2D in the dominant model adjusted by potential 
confounding factors. Subgroup analysis was conducted by strata of gender. Student’s t-
tests on continuous values of T2D related quantitative traits were compared between risk 
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allele carriers and non-carriers in control subjects. In addition, linkage disequilibrium and 
haplotype analysis were performed using Haploview 4.2.  
Results: Adjusted logistic regression demonstrated that SNP rs7903146 (OR=2.01, 
p=0.065) minor allele showed a marginal significance with the increased risk of T2D in 
AAs; minor alleles of SNP rs11196205 (OR=0.58, p=0.059) and rs7895340 (OR=0.59, 
p=0.069) showed marginal significance with the protective effect for the risk of T2D in 
HAs. After stratification by gender, for both ethnicities, SNPs with marginal significance 
from the gender-combined analyses became statistically significant with the same trend 
for the risk of T2D when analyses were done in males: SNPs rs7903146 (OR=2.86, 
p=0.013) for AAs, rs11196205 (OR=0.35, p=0.033) and rs7895340 (OR=0.33, p=0.024) 
for HAs. In addition, SNP rs7901695 and rs4506565 (OR=2.69, p=0.025) were found to 
be significantly associated with the risk of T2D in AA males. In addition, T2D related 
quantitative trait analysis showed that compared to non-minor allele carriers (TT) of SNP 
rs12255372, minor allele carriers had significantly higher means of BMI (p= 0.036), DBP 
(p=0.0099), numbers of components of Mets (p< 0.0001.) and significantly lower mean 
values of HDL-C (p=0.020) and adiponectin (p=0.017) in AA non-diabetic controls.  
Conclusions: The present study demonstrated ethno-specific genetic association between 
variants in TCF7L2 gene and the risk of T2D and related metabolic traits among Haitian 
Americans and African Americans. Our results suggested potential issues regarding 
population stratification within Blacks. The lack of genetic association studies in Blacks, 
especially for Haitian Americans, warrants further replication study with larger samples.  
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Introduction 
Diabetes is a significant public health issue globally. The International Diabetes 
Federation estimated that 425 million people live with diabetes in 2017 and this number 
is projected to rise to 629 million by 2045 [1]. Type 2 diabetes (T2D) accounts for 90% to 
95% newly diagnosed diabetes. In the United States, approximately 30.3 million US 
people, or 9.4% of the U.S. population had diabetes and an estimated 33.9% of U.S. 
adults aged 18 years or older (84.1 million people) had prediabetes [2]. African 
Americans are disproportionately affected by diabetes. 12.7% of African Americans aged 
18 years or older have diabetes, compared to 7.4% of non-Hispanic whites in 2015 [2]. 
African Americans are almost twice as likely to be diagnosed with diabetes as non-
Hispanic whites. In addition, they were more likely to suffer from complications of 
diabetes, such as high blood pressure end-stage renal disease and lower extremity 
amputations and were twice as likely as non-Hispanic Whites to die from complications 
of diabetes [3].  
Because of the high prevalence of diabetes in the African American community, it 
has been suggested that African Americans may be more susceptible to the disease 
compared with Whites through direct genetic propensity or gene–unfavorable 
environmental interactions (e.g. high fat and sugar intake) [4, 5]. Strong genetic 
component to T2D have been discovered by family history and concordance studies [6-
10]. Recent genetic studies, especially high throughput genome-wide association studies 
(GWAS), have identified a multitude of variants associated with T2D. To date, TCF7L2 
(transcription factor 7-like 2) confers the strongest statistical evidence for the association 
with the risk of T2D.  TCF7L2 spans a 215,863 bases region on chromosome 10q25.3, 
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and has 17 exons, of which five are alternative yielding different slicing possibility [11, 
12]. The TCF7L2 gene product is a high-mobility box-containing transcription factor 
which is a ubiquitous protein that belongs to a family of TCF/lymphoid enhancer factor 
[13]. TCF7L2, together with β-catenin is a well-known bipartite transcription factor in the 
canonical Wnt pathway. Efforts to elucidate the potential role of TCF7L2 in the Wnt 
signaling pathway related to incretin hormone regulation, β-cell proliferation and 
apoptosis, and glucose production have been documented [14-16]. The involvement of 
TCF7L2 in all these pathway puts this gene in a critical role suggesting strong 
relationship of polymorphisms of TCF7L2 with type 2 diabetes (T2D). In addition, more 
recent studies also revealed that potential role of TCF7L2 in adipogenesis and 
demonstrated variants in this gene could modify the risk of developing obesity and 
Metabolic Syndrome [17-20]. 
Although associations between various SNPs in TCF7L2 and T2D were observed 
across ethnically diverse populations, results from studies conducted in African 
Americans have been inconsistent [21]. Currently in the United States, all Blacks, 
regardless of ancestry or country of origin, have been grouped as one category for 
research purpose. This practice could mask the true association among diverse subgroups 
within Black population due to genetic heterogeneity. Beyond genetic variation, 
environmental factors, especially diet pattern, lifestyle, and physical activity among 
subgroups of Blacks may modify the risk of T2D for people carrying deleterious genes 
based on “Thrift Gene” theory and consequently complicated the results from genetic 
association studies in Black people [22, 23]. Haitian Americans are one of the fastest 
growing Caribbean immigrant populations in the United States. According to the U.S. 
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Census, an estimated 929,074 Haitian Americans were living in the U.S. in 2013, of 
which approximately half of them reside in Florida, and nearly one third (~290,000) live 
in the Miami metro area [24]. Previous studies indicated that Haitian Americans have 
specific characteristic in their genetic background, eating patterns and lifestyles which 
distinguish them from African Americans [25]. Haitian Americans represent a unique 
ethnic group in South Florida but very often they were grouped with other Blacks with 
African origins for health research. Thus, translation and generalization of the results 
from genetic association conducted in African Americans to Haitian Americans should be 
done with caution and warrants further replication. Studies from our research group also 
suggested Haitian Americans may have different genetic makeup than African Americans 
[26]. By far, studies looking at health disparity in a separated Haitian American 
population is limited, including genetic studies. The primary purpose of this study was to 
examine six most studied SNPs in TCF7L2 gene: rs7903146, rs12255372, rs11196205, 
rs7901695, rs7895340 and rs4506565 in relation to the risk of T2D and related metabolic 
quantitative traits in individuals with and without T2D in African Americans and Haitian 
Americans from South Florida. 
Methodology 
 Samples for this study were from participants of an earlier cross-sectional study of 
N = 485 participants: Haitian American (HA) (N = 240), and African American (AA) (N 
= 245). These samples were collected from 2008–2010, of which 249 subjects with type 2 
diabetes and 236 who had not developed type 2 diabetes were recruited. By study design, 
approximately half of each racial/ethnic minority in this study had type 2 diabetes and the 
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rest were free of diabetes. Participants were initially recruited by random selection from 
randomly generated mailing lists. The lists of addresses were purchased from Knowledge 
Base Marketing, Inc., Richardson, TX, USA. Approximately 7,550 letters were mailed to 
African Americans with and without T2D. Of the participants who received letters, 4% 
responded. Because we did not have a similar mailing list database for Haitian 
Americans, we recruited these participants from community-based sources: (a) local 
diabetes educators and community health practitioners in Miami-Dade and Broward 
Counties; (b) Florida International University (FIU) faculty, staff, and students; (c) 
several active adult apartment complexes; and (d) print advertisements and radio 
advertisements. Interested participants were interviewed by phone, at which time the 
study purpose was explained and information on age, self-identified ethnicity, gender, 
self-reported T2D status (confirmed by fasting plasma glucose (> 126 mg/dL) and/or A1c 
(>6.5%), years since diagnosis, and initial treatment modalities (oral glucose-lowering 
drugs and insulin)) were obtained. If a subject was determined to be eligible, then his or 
her participation was requested at the Human Nutrition Laboratory at FIU. Participants 
were instructed to fast at least 8 hours prior to their blood collection. Written consent in 
English, or Creole was obtained from the participants on their first visit to the laboratory. 
Validated questionnaires were used to collect information on demographics, dietary 
intake and physical activities [27-29]. A total of 12 participants (HA = 8; and AA= 4) 
who reported not having diabetes were reclassified in the study as having T2D according 
to American Diabetes Association (ADA) standards. These participants were provided 
with a copy of their laboratory results and referred to their physicians.  
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Measurements 
Anthropometric measurements and biospecimen analyses 
Data for serum biomarkers were available from our parent database. Briefly, height, 
weight, and blood pressure were measured using standard methodology with detailed 
description in our previous study [30]. Twenty ml of venous blood was collected from 
each participant after an overnight fast (at least 8 hours) by a certified phlebotomist. 
Fasting plasma glucose (FPG) levels in serum were quantified using hexokinase method. 
Whole blood was used to measure A1C (glycated hemoglobin) using Roche Tina Quant 
method (Laboratory Corporation of America, Lab Corp, FL, USA). Automatic chemical 
analyzer was employed to determine high-density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (TC). 
Serum insulin levels were determined using the Human Insulin ELISA kit from Millipore 
(St Charles, MZ, USA). Adiponectin was measured in the PI’s lab using an enzyme-
linked immunosorbent assay (ELISA) (Linco Research Inc, St. Charles, MO, USA). The 
updated homeostatic model assessment (HOMA2) was based on the Oxford University 
HOMA2 calculator (www.ocdem.ox.ac.uk) and was used to estimate beta cell function 
(HOMA2-β), insulin resistance (HOMA2-IR), and insulin sensitivity (HOMA2-IS) [24]. 
The presence of Metabolic Syndrome (MetS) and number of MetS components (Yes or 
No) was determined based on the National Cholesterol Education Program Adult 
Treatment Panel III criteria (NCEP-ATP III) [31]. 
Isolation of DNA and genotyping 
Genomic DNA was isolated from the whole blood using QIAamp DNA Blood mini 
kit (Qiagen, Hilden, Germany), according to the vender’s recommended protocol. Quality 
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and quantity of the isolated DNA was assessed by using 2000c nanodrop 
spectrophotometer (Thermo Scientific, USA). Genotyping for all six SNPs was 
performed by real-time PCR amplification on BioRad CFX96 real time PCR instrument 
(Hercules, CA) using commercially available TaqMan allelic discrimination assays 
(LifeTech, Foster City, CA). To ensure reproducibility and reliability of genotyping 
method, 10% of the DNA samples were duplicated during genotyping. We obtained a 
100% concordance between the genotyped duplicate samples for the single nucleotide 
polymorphism (SNP).  
Statistical analysis 
Statistical analysis was conducted using SAS version 9.4 (SAS Institute Inc., Cary, 
NC, USA). The sample size of the study had sufficient statistical power (>80%) to detect 
odds ratio of 1.5 or more, for matched case and control at significance threshold of 0.05 
[26]. All statistical tests were two-tailed, and the threshold for statistical significance was 
set at P≤0.05. Genotype counts in each SNP was checked for Hardy-Weinberg 
equilibrium (HWE) in controls using the Chi-squared goodness-fit test. The distributions 
of the metabolic quantitative traits, such as lipid profiles, HOMA2 index, FPG, A1C, etc., 
were markedly skewed, which were normalized, to a large extent, by their logarithmic 
transformation. Therefore, t-tests on continuous values of these quantitative traits were 
performed on logarithmically transformed values. Demographic and clinical information 
between cases and controls were compared using student’s t-test for continuous variables, 
and Chi-squared test for categorical variables. Dominant genetic model (noncarrier=0, 
heterozygous and homozygous=1) was selected for genetic association analysis, due to a 
small sample size for homozygotes of minor alleles. Logistic regression models were 
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used to calculate odds ratios (OR) and 95% confidence intervals (CIs) to assess the 
relationship of all SNPs with binary outcome for case-control status (T2D=Yes/No), and 
model was adjusted by potential confounding factors such as age, sex, BMI, physical 
activities and calorie intake. Spearman's rank-order correlation were applied to evaluate 
the correlation coefficient between continuous variables and discrete variables. Haplotype 
analysis and linkage disequilibrium (LD) coefficients were calculated using Haploview 
4.2 (Cambridge, MA, USA) [32].  
Results 
General characteristics 
This study included N=240 Haitian Americans (n=123 with T2D and n=117 without 
T2D) and N= 245 African Americans (n=126 with T2D and n=119 without T2D). 
Characteristics of the participants were presented as comparison of means ± SD by 
diabetes status for both ethnic groups (Table 1a and 1b). Briefly, individuals with T2D 
(cases) were older than those without T2D (controls) in both Haitian Americans and 
African Americans. Compared to individuals without T2D, individuals with T2D for both 
ethnic groups had significantly higher mean values of waist circumference, fasting 
plasma glucose, A1C (%), as well as higher percentage of MetS and higher number of 
MetS components and significantly lower mean values of HOMA2_B. Significant 
differences on mean values of BMI, SBP, TG and indexes of HOMA2_IR and 
HOMA2_IS and adiponectin between cases and controls were only present in African 
Americans whilst significant differences on mean values of insulin, kcal (calorie 
intake/day) and PA_MET_wk (weekly physical activity) were only present in Haitian 
Americans.  
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Distribution of TCF7L2 polymorphisms 
All cases and controls were genotyped for the six SNPs. None of the 6 TCF7L2 
SNPs showed any deviation from Hardy-Weinberg equilibrium in controls. Table 2 shows 
genotype distribution of all 6 PPARGC1A SNPs in the case-control sample for both 
ethnicities. Genotype distribution and allele frequency were not significantly different 
between subjects with diabetes and subjects without diabetes. Linkage disequilibrium 
analyses showed both similarity and difference between two ethnic groups. Two 
haplotype blocks with the same combinations for both ethnic groups were defined by 
using Four Gamete method (Figure 1a and 1b) [33]. The first block was established by 
three consecutive SNPs: rs7901695, rs450565 and rs7903146. The second block was 
established by three consecutive SNPs: rs7895340, rs11196205 and rs12255372. SNPs 
within each block were in a strong linkage disequilibrium. When looking pairwise LD, 
compared to African Americans, Haitian American tend to have more distinguished block 
as defined by low value of r2 (r2=0.22 for HA and r2=0.66 for AA, respectively) between 
two haplotype blocks. 
Correlations between TCF7L2 polymorphisms and type 2 diabetes 
Table 3a and 3b shows results from unconditional logistic regression by the 
dominant genetic model with adjustment for covariates (BMI, age, gender, physical 
activity, and calories intake) for African Americans and Haitian Americans, respectively. 
Though we didn't find any significant associations with the risk of T2D which was 
consistent with the results from genotype distribution analyses, SNP rs7903146 
(OR=1.71, p=0.065) minor allele showed a marginal significance with the increased risk 
of T2D in African Americans; minor alleles of SNP rs11196205 (OR=0.58, p=0.059) and 
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rs7895340 (OR=0.59, p=0.069) showed marginal significance with the protective effect 
for the risk of T2D in Haitian Americans. Effect modification of sex on TCF7L2 SNPs 
association with T2D was also explored by stratification by sex adjusted for age, BMI, 
physical activity, and calories intake. Interestingly, for both ethnic groups, significant 
associations were only found in male subjects. Of note, for both ethnic groups, SNPs with 
marginal significance from the gender-combined analyses became statistically significant 
with the same trend for the risk of T2D when analyses were done in males: SNPs 
rs7903146 (OR=2.86, p=0.013) for African Americans, rs11196205 (OR=0.35, p=0.034) 
and rs7895340 (OR=0.33, p=0.024) for Haitian Americans. In addition, SNP rs7901695 
(OR=2.69, p=0.025) was found to be significantly associated with the risk of T2D in 
males of African American. Same result was also found for rs4506565 due to its strong 
LD with rs7903146 (D=1, r2=0.99). 
Correlations between TCF7L2 polymorphisms and metabolic traits 
Comparison of metabolic traits between non-risk allele carriers and risk allele 
carriers were conducted in subjects without T2D (controls). For African Americans, the 
fasting glucose level was significantly higher in non-risk allele carriers of SNPs 
rs4566565 and rs7901695, compared to the risk allele carriers (p=0.017). The difference 
stayed significant after covariates adjustment (BMI, age, gender, physical activity, and 
calories intake) for both SNPs. In addition, for African Americans, we identified 
consistent trends in metabolic traits when comparing minor allele carriers with non-
carriers of SNP rs12255372 in non-diabetic controls (table 4). Compared to non-carriers, 
minor allele carriers had significantly higher means of BMI (p= 0.036), DBP (p=0.0099), 
numbers of components of MetS (p< 0.0001.) and significantly lower mean values of 
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HDL-C (p=0.020) and adiponectin (p=0.017). Results stayed significant after covariates 
adjustment. Spearman's rank-order correlation also demonstrated that serum level of 
adiponectin was negatively associated with numbers of components of Mets (correlation 
coefficient = -0.22, p= 0.014) in African American non-diabetic controls. 
Discussion 
Type 2 diabetes are highly prevalent and lead to significant morbidity and mortality. 
This is particularly true for African Americans. Compared to non-Hispanic whites, 
African American adults are 80 percent more likely to have been diagnosed with 
diabetes; 4.2 times more likely to be diagnosed with end stage renal disease; 3.5 times 
more likely to be hospitalized for lower limb amputations and twice as likely as non-
Hispanic Whites to die from complications of diabetes [34]. Efforts have been made to 
understand the genetic variation that underlies T2D in African Americans and other 
individuals of more recent African descent. However, inconsistent replication of results is 
often present when studying genetic associations in African Americans. Studies 
suggested potential issues regarding racial designations as a common practice to group 
people but very often ignoring ethnic and sociocultural diversity [35]. TCF7L2 is one of 
the top candidate genes for T2D and recent studies also reveal its association with obesity 
and metabolic syndrome [17-20]. The present study demonstrated ethno-specific genetic 
association with T2D and related metabolic traits among Haitian Americans and African 
Americans and suggested potential issues regarding population stratification within 
Blacks. 
TCF7L2 is a transcription factor involved in the Wnt signaling pathway. Functional 
studies revealed that Wnt signaling pathway plays important role in glucose homeostasis 
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[14-16]. Variants within intron 4 and intron 5 of the TCF7L2 were the most studied SNPs 
and by far yielded the strongest signal with the risk of T2D [21, 36-38]. Several studies 
led the way in investigating the role of variations in TCF7L2 for the risk of T2D in 
populations of African descent. One hospital-based case–control study conducted in 
Kumasi, Ghana found a significant association of TCF7L2 SNP rs7903146 with T2D; the 
risk allele confers 1.39-fold increased risk for type 2 diabetes [39]. In line with this 
finding, another study in Cameroonians confirmed such association though sample size is 
limited (n=74) [40]. Research in individuals of North African (Moroccan) also 
demonstrated reproducible association between SNP rs7903146 and the risk of T2D [41]. 
Several investigations in African Americans also demonstrated similar trends as seen in 
Africans. The Atherosclerosis Risk in Communities (ARIC) study found that African 
Americans with the risk allele at SNP rs7903146 had a higher risk of T2D, especially for 
individual with adverse metabolic syndrome (e.g. high BMI and low HDL) [42]. 
Similarly, a study of an African-American population enriched for nephropathy showed 
that 5 SNPs (rs7903146, rs7901695, rs7895340, rs11196205, and rs12255372) in 
TCF7L2 were significantly associated with T2D, among which rs7903146 and rs7901695 
demonstrated most significant associations [42]. In a multi-ethnic youth study, 
researchers found that each copy of risk allele of SNP rs7903146 was significantly 
associated with a 1.97-fold increased odd for type 2 diabetes in African Americans [43]. 
Consistent with these findings, the results from the present study showed that SNP 
rs7903146 (OR=1.71, p=0.065) minor allele was marginally significant with the risk of 
T2D in African Americans. The estimates of allele frequencies and LD pattern among our 
studied individuals were consistent with other published reports in African Americans, 
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which suggested representativeness of our samples [42-44]. In addition, we found that 
when conducting gender-specific analysis, SNP rs7903146 (OR=2.86, p=0.013) along 
with two additional SNPs (rs7901695 and rs4506565) were significantly associated with 
the risk of T2D in males whilst no such significant association were observed in females. 
Recent evidence from heritability studies and GWASs also demonstrated that common 
genetic variation influences many diseases and medically relevant traits in a sex-
dependent manner [46]. The results from our study suggested gender-dependent effect on 
the risk association for variants in TCF7L2.  
However, our results were different from those that failed to identify such 
association. One study to investigate two TCF7L2 SNPs s7903146 and rs12255372 in 
relation to the risk of T2D, glucose homeostasis traits and gene expression did not find 
any significance in African Americans [47]. Researchers for the Diabetes Prevention 
Program performed Cox regression model to predict the progression to type 2 diabetes in 
individual with impaired glucose intolerance. Homozygotes of risk T allele at rs7903146 
conferred excess risk of incident diabetes only in Hispanics but not in African Americans 
[48]. The discrepancy among African Americans could be due to different study design, 
unadjusted analysis complicated by confounding factors, especially life style and eating 
pattern, and genetic heterogeneity within Blacks. Of note, two previous studies yielding 
significant association with TCF7L2 gene did adjust the ancestry markers for association 
analysis [42, 43]. To date, SNP rs7903146 was most significantly associated with T2D, 
with association observed across diverse populations. Our study contributed additional 
evidence to confirm such association in African Americans.  
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Haitians Americans are one of those high-risk populations for T2D. Though official 
data for Haitian Americans are not available, due to being grouped with other Blacks for 
health studies, a small-scale study conducted in a Haitian community (Little Haiti) in the 
Miami-Dade County, FL, estimated a 33% prevalence of diabetes among Haitian 
immigrants [49]. By far, only one study conducted in African-Caribbeans investigated the 
association between variants (SNPs rs7903146 and rs12255372) in TCF7L2 and the risk 
of T2D and found no significant association (p=0.17) [50]. Consistent with this finding, 
we didn’t find any significant association of these two SNPs with T2D. The minor allele 
frequency of TCF7L2 SNPs rs7903146 and rs12255372 and LD pattern between these 
two SNPs in the present study were also comparable to the finding in aforementioned 
research, which further validated our study. In addition, we found that minor alleles of 
SNPs rs11196205 (OR=0.58, p=0.059) and rs7895340 (OR=0.59, p=0.069) showed 
marginal significance with the protective effect for the risk of T2D in Haitian Americans. 
Modification effect by sex on association with T2D was also noticed in Haitian 
American. The trend observed in Haitian Americans was similar as that found in African 
Americans. Both SNPs rs11196205 and rs7895340 with marginal significance in 
combined gender analysis demonstrated significant association with the risk of T2D in 
male subjects (OR=0.35, p=0.034; OR=0.34, p=0.024, respectively). This finding agreed 
with a previous study which showed that minor alleles of SNPs rs7895340 and rs1196205 
were significantly associated with reduced risk of T2D in African Americans but contrast 
with finding from studies in other populations [42, 51, 52].  Due to limited statistical 
power, replication on such association is warranted for further validation, especially in 
gender-specific investigation. Collectively, the results from the present study 
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demonstrated different risk association of TCF7L2 SNPs between Haitian Americans and 
African Americans. Previous studies suggested Haitian Americans may have specific 
characteristics which distinguish them from African Americans. Apart from African 
descent, populations of Haitian Americans also have genetic heritage from France, and 
Spain [53]. Haitian Americans have a unique dietary pattern featured by two meals a day 
with starch predominantly as energy source. One study on eating behavior showed that 
Haitian Americans and African Americans have significantly different healthy eating 
index (HEI) scores, and levels of physical activity [54]. These unique features of Haitian 
Americans in their genetic background and lifestyles may suggest Haitian Americans 
should be independently and separately evaluated from the African Americans. 
The metabolic syndrome is a cluster of factors which requires the presence of least 
three of the five following components: central obesity, high blood pressure, elevated 
triglycerides, low high-density lipoprotein cholesterol (HDL), or fasting hyperglycemia 
[31]. Metabolic syndrome increased the risk of T2D and is prevalent in patients with T2D 
[55, 56]. Studies also suggested that metabolic syndrome and T2D present an altered lipid 
metabolism with increased triglyceride levels and postprandial dyslipidemia [57-59]. As 
such, it has been speculated that T2D and Metabolic Syndrome may share some common 
pathology and mediators including genetic predisposition in energy metabolism and 
substrate utilization. In line with this hypothesis, the T2D-related genetic variants showed 
pleiotropic effects to multiple MetS-related traits, which included blood pressure, obesity, 
lipids profiles and blood glucose [20, 59-62]. From the present study, consistent trends in 
metabolic traits were found when comparing minor allele carriers with non-carriers of 
SNP rs12255372 in African Americans non-diabetic controls. Compared to non-carriers 
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of SNP rs12255372, minor allele carriers had significantly higher mean values of BMI 
(p= 0.036), DBP (p=0.010), components of Mets (p=0.035) and significantly lower mean 
values of HDL-C (p=0.02). Two previous studies which investigated the association 
between SNP rs12255372 and metabolic traits demonstrated minor allele in this SNP was 
significantly and positively associated with dyslipidemia [19, 63]. Functional studies 
suggested TCF7L2 may involve in adipogenesis and adipocyte differentiation via 
measuring the main adipokines present in mature adipocytes [63-65]. In the present 
study, we additionally found minor allele carriers of SNP rs12255372 had significantly 
reduced adiponectin level (p=0.017) compared to non-carriers in African American non-
diabetic controls. Adiponectin is an important adipocytokine secreted exclusively by 
adipocytes and plays an important role in glucose and lipid homeostasis, inflammation 
and oxidative stress [66]. Various studies suggest that circulation adiponectin levels are 
negatively associated with waist circumference, triglycerides, insulin resistance and 
arterial blood pressure whilst positively associated with plasma HDL level [66]. In line 
with these findings, adiponectin level was significantly associated with reduced 
components of Mets in our study (p=0.014). Collectively, the consistent trends in the 
association between SNP rs12255372, metabolic syndrome traits and serum adiponectin 
level suggested SNP rs12255372 could be the potential genetic variant with pleiotropic 
effects on multiple MetS-related traits and warrants replication by a larger sample and 
further investigation in functional mechanism. 
We must be cautious when extrapolating our results since there are some limitations. 
One limitation was the relatively small sample size which may have decreased the 
statistical power to detect significant associations. The cross-sectional design of the study 
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precluded the establishment of cause and effect. Further study is needed to investigate the 
nature of the associations found in the present study. In addition, generalization of the 
results from the present study may be made with caution due the selection bias caused by 
recruiting method. Haitian Americans, and African Americans may not be representative 
of the same ethnicities residing in other parts of Florida or USA. In this study, the 
heterogeneity within the African American and Haitian American population cannot be 
ruled out and thus residual confounding is still a concern. However, both cases and 
controls were selected from the same population pool and geographic area, with 
information on ethnicity up to two generations, for each respective ethnicity. When 
conducting genetic association in individuals with African origin, a common practice is 
to include ancestry marker to adjust the genetic heterogeneity. However, as T2D is a 
complex disease with strong environmental influence. Merely adjusting genetic 
heterogeneity while ignoring the environmental variations (e.g. culture, lifestyle, eating 
pattern, et al) may mask the true association in Black people with diverse ethnicities. As 
seen in studies of Samoa and American Samoa, same genetic pool with distinct eating 
behaviors yielded different genetic association with chronic diseases [67, 68]. 
Conclusion 
 This study demonstrated ethno-specific associations of TCF7L2 SNPs with the risk 
T2D and metabolic traits in African Americans and Haitian Americans and suggested that 
the two ethnic groups may have different genetic risk factors under the complex 
interactions between genetic and environmental factors.  
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Table 1a. Anthropometric, demographic and metabolic characteristics of Haitian 
Americans 
 Without T2D With T2D  
 (n=117) case (n=123) p* value 
Age (Years) 54.08±11.01 58±9.99 0.0042 
Female (N (%)) 59 (50.43%) 71 (57.72%) 0.26 
BMI (kg/m2) 28.41±1.18 29.11±1.2 0.28 
Waist circumference (cm) 95.16±1.13 98.93±1.13 0.015 
SBP (mm of Hg) 142.84±1.18 146.03±1.18 0.30 
DBP (mm of Hg) 89.51±1.15 90.48±1.15 0.56 
Triglycerides (mg/dl) 92.05±1.59 99.40±1.57 0.19 
Total cholesterol (mg/dl) 194.79±1.21 188.05±1.25 0.19 
HDL-C (mg/dl) 51.33±1.3 51.71±1.33 0.83 
LDL-C (mg/dl) 119.51±1.34 111.29±1.37 0.07 
FPG (mmol/L) 97.55±1.18 144.82±1.5 <.0001 
A1C (%) 5.93±1.09 8.09±1.32 <.0001 
Insulin 8.58±1.8 6.44±2.06 0.0008 
HOMA2_B 90.09±1.59 37.7±2.4 <.0001 
HOMA2_IR 1.18±1.7 1.18±1.75 0.98 
HOMA2_IS 85.24±1.71 85.04±1.75 0.97 
Number of MetS components 1.85±1.00 3.04±0.94 <.0001 
Presence of MetS (N (%)) 30 (25.64%) 87 (70.73%) <.0001 
Adiponectin 14.51±1.76 13.35±1.75 0.25 
kcal 1673.55±1.76 1442.6±1.76 0.043 
PA_MET_wk 23.85±5.4 12.56±5.02 0.0047 
Values are unadjusted mean ± SD for continuous variables or N for categorical variables. 
* Derived from t-test for means or chi-square test for percentage differences between 
cases and controls. BMI= body mass index; SBP= systolic blood pressure; DBP= 
diastolic blood; HDLC= high-density lipoprotein cholesterol; LDL-C=low density 
lipoprotein cholesterol;FPG= fasting plasma glucose; A1C= hemoglobin A1C; MetS= 
Metabolic Syndrome; PA_MET_wk= physical activity  measured by metabolic equivalents 
(MET) per week 
 
 
 
 
 
 
 
 
 
 
 
113 
 
Table 1b. Anthropometric, demographic and metabolic Characteristics of African 
Americans 
 Without T2D With T2D   
  (n=119) case (n=126) p* value 
Age (Years) 50.74±8.54 54.35±9.84 0.0025 
Female (N (%)) 59 (49.8%) 65 (51.59%) 0.75 
BMI (kg/m2) 30.36±1.23 34.76±1.26 <.0001 
Waist circumference (cm) 100.47±1.15 112.33±1.17 <.0001 
SBP (mm of Hg) 130.86±1.14 139.77±1.16 0.0003 
DBP (mm of Hg) 86.86±1.15 89.27±1.13 0.11 
Triglycerides (mg/dl) 104.56±1.6 121.91±1.65 0.014 
Total cholesterol (mg/dl) 186.18±1.22 184.55±1.26 0.75 
HDL-C (mg/dl) 49.08±1.30 47.29±1.33 0.29 
LDL-C (mg/dl) 110.34±1.36 104.23±1.54 0.24 
FPG (mmol/L) 94.73±1.14 135.64±1.48 <.0001 
A1C (%) 5.85±1.07 7.44±1.26 <.0001 
Insulin 10.01±2.01 11.40±2.39 0.20 
HOMA2_B 106±1.54 57.15±2.17 <.0001 
HOMA2_IR 1.36±1.91 1.67±1.93 0.016 
HOMA2_IS 73.65±1.91 59.50±1.92 0.014 
Number of MetS components 1.95±1.24 3.40±0.97 <.0001 
Presence of MetS (N (%)) 35 (29.41%) 107 (84.72%) <.0001 
Adiponectin 19.46±1.71 23.45±1.88 0.014 
kcal 2258.15±1.93 1965.10±1.86 0.09 
PA_MET_wk 19.28±6.91 16.94±5.66 0.61 
Values are unadjusted mean ± SD for continuous variables or N for categorical variables. 
* Derived from t-test for means or chi-square test for percentage differences between 
cases and controls. BMI= body mass index; SBP= systolic blood pressure; DBP= 
diastolic blood; HDLC= high-density lipoprotein cholesterol; LDL-C=low density 
lipoprotein cholesterol; FPG= fasting plasma glucose; A1C= hemoglobin A1C; MetS= 
Metabolic Syndrome; PA_MET_wk= physical activity measured by metabolic equivalents 
(MET) per week 
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* Derived from chi-square test; MAF= minor allele frequencies 
Table 2. Genotype distribution and minor allele frequency of all 6 TCF7L2 SNPs in the case-
control samples for both ethnicities 
TCF7L2 SNPs Haitian American   African American   
rs12255372 
Without 
T2D n (%) 
With T2D  
n (%) 
p* value 
Without 
T2D n (%) 
With T2D  
n (%) 
p* value 
GG 52 (44.83%) 68 (55.28%) 
0.27 
55 (46.22%) 64 (50.79%) 
0.17 GT 55 (47.41%) 47 (38.21%) 52 (43.70%) 57 (45.24%) 
TT 9 (7.76%) 8 (6.50%) 12 (10.08%) 5 (3.97%) 
MAF (%)        
T 31.47% 25.61% 0.51 31.93% 26.59% 0.19 
rs11196205             
CC 70 (59.83%) 84 (68.29%) 
0.37 
74 (62.18%) 76 (60.32%) 
0.76 GC 40 (34.19%) 32 (26.02%) 38 (31.93%) 42 (33.33%) 
GG 7 (5.98%) 7 (5.69%) 7 (5.88%) 8 (6.35%) 
MAF (%)        
G 23.08% 18.70% 0.55 21.85% 23.02% 0.98 
rs7903146        
CC 58 (49.57%) 63 (51.22%) 
0.95 
57 (47.90%) 49 (38.89%) 
0.27 CT 49 (41.88%) 49 (39.84%) 51 (42.86%) 67 (53.17%) 
TT 10 (8.55%) 11 (8.94%) 11 (9.24% 10 (7.94%) 
MAF (%)      
T 29.49% 28.86% 0.35 30.67% 34.52% 0.36 
rs7901695        
TT 36 (30.77%) 32 (26.02%) 
0.62 
40 (33.61%) 35 (27.78%) 
0.46 TC 52 (44.44%) 62 (50.41%) 58 (48.74%) 62 (49.21%) 
CC 29 (24.79%) 29 (23.58%) 21 (17.65%) 29 (23.02%) 
MAF (%)        
C 47.01% 48.78% 0.94 42.02% 47.62% 0.21 
rs7895340        
AA 69 (58.97%) 82 (66.67%) 
0.44 
71 (59.66%) 76 (60.32%)  
GA 41 (35.04%) 34 (27.64%) 41 (34.45%) 42 (33.33%) 0.98 
GG 7 (5.98%) 7 (5.69%) 7 (5.88%) 8 (6.35%)  
MAF (%)        
G 23.50% 19.51% 0.50 23.11% 23.02% 0.98 
rs4506565     
   
AA 35 (29.91%) 32 (26.02%) 
0.70 
40 (33.61%) 35 (27.78%) 
0.52 AT 52 (44.44%) 61 (49.59%) 57 (47.90%) 62 (49.21%) 
TT 30 (25.64%) 30 (24.39%) 22 (18.49%) 29 (23.02%) 
MAF (%)        
T 47.86% 49.19% 0.88 42.44% 47.62% 0.25 
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Table 3a. Unconditional logistic regression by the dominant genetic model with adjustment for 
covariates for African Americans. 
African Americans (all subjects) 
SNPs 
Without T2D 
N (%) 
With T2D 
N (%) 
OR (95% CI) p* value 
rs12255372 GG 56 (46.22%) 64 (50.79%) 1 (reference) 0.15 
 GT+TT 64 (53.78%) 62 (51.43%) 0.66 (0.38-1.17) 
rs11196205 CC 74 (62.18%) 76 (60.32%) 1 (reference) 0.77 
 GC+GG 45 (37.82%) 50 (39.68%) 1.09 (0.61-1.94) 
rs7903146 CC 57 (47.90%) 49 (38.89%) 1 (reference) 0.065 
 CT+TT 62 (52.10%) 77 (61.11%) 1.71 (0.97-3.04) 
rs7901695 TT 40 (33.61%) 35 (27.78%) 1 (reference) 0.20 
 TC+CC 79 (66.39%) 91 (72.22%) 1.49 (0.81-2.73) 
rs7895340 AA 71 (59.66%) 76 (60.32%) 1 (reference) 0.99 
 GA+GG 48 (40.34%) 50 (39.68%) 1.00 (0.56-1.76) 
rs4506565 AA 40 (33.61%) 35 (27.78%) 1 (reference) 0.20 
  AT+TT 79 (66.39%) 91 (72.22%) 1.49 (0.81-2.73) 
AA (Gender=Female) 
SNPs 
Without T2D  
N (%) 
With T2D 
 N (%) 
OR (95% CI) p* value 
rs12255372 GG 26 (44.07%) 32 (49.23%) 1 (reference) 0.50 
 GT+TT 33 (55.93%) 33 (50.77%) 0.74 (0.32-1.74) 
rs11196205 CC 39 (66.10%) 38 (58.46%) 1 (reference) 0.51 
 GC+GG 20 (33.90%) 27 (41.54%) 1.34 (0.56-3.19) 
rs7903146 CC 24 (40.68%) 28 (43.08%) 1 (reference) 0.89 
 CT+TT 35 (59.32%) 37 (56.92%) 0.94 (0.40-2.19) 
rs7901695 TT 15 (25.42%) 20 (30.77%) 1 (reference) 0.49 
 TC+CC 44 (74.58%) 45 (69.23%) 0.72 (0.29-1.81) 
rs7895340 AA 37 (62.71%) 38 (58.46%) 1 (reference) 0.72 
 GA+GG 22 (37.29%) 27 (41.54%) 1.17 (0.50-2.76) 
rs4506565 AA 15 (25.42%) 20 (30.77%) 1 (reference) 0.49 
  AT+TT 44 (74.58%) 45 (69.23%) 0.72 (0.29-1.81) 
AA (Gender=Male) 
SNPs 
Without T2D  
N (%) 
With T2D  
N (%) 
OR (95% CI) p* value 
rs12255372 GG 29 (48.33%) 32 (52.46%) 1 (reference) 0.22 
 GT+TT 31 (51.67%) 29 (47.54%) 0.61 (0.28-1.34) 
rs11196205 CC 35 (58.33%) 38 (62.30%) 1 (reference) 0.74 
 GC+GG 25 (41.67%) 23 (37.70%) 0.88 (0.40-1.93) 
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rs7903146 CC 33 (55.00%) 21 (34.43%) 1 (reference) 0.013 
 CT+TT 27 (45.00%) 40 (65.57%) 2.86 (1.25-6.54) 
rs7901695 TT 25 (41.67%) 15 (24.59%) 1 (reference) 0.025 
 TC+CC 35 (58.33%) 46 (75.41%) 2.69 (1.14-6.37) 
rs7895340 AA 34 (56.67%) 38 (62.30%) 1 (reference) 0.61 
 GA+GG 26 (43.33%) 23 (37.70%) 0.82 (0.37-1.79) 
rs4506565 AA 25 (41.67%) 15 (24.59%) 1 (reference) 0.025 
  AT+TT 35 (58.33%) 46 (75.41%) 2.69 (1.14-6.37) 
*P value and odds ratios (OR) with 95% confidence interval (CI) were calculated using unconditional 
logistic models adjusted by BMI, gender, age, physical activity and calorie intake; AA= African 
American. 
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Table 3b. Unconditional logistic regression by the dominant genetic model with adjustment for 
covariates for Haitian American. 
 
Haitian Americans (all subjects) 
SNPs 
Without T2D  
N (%) 
With T2D  
N (%) 
OR (95% CI) 
p* 
value 
rs12255372 GG 52 (44.83%) 68 (55.28%) 1 (reference) 0.28 
 GT+TT 64 (55.17%) 55 (44.72%) 0.74 (0.44-1.27)  
rs11196205 CC 70 (59.83%) 84 (68.29%) 1 (reference) 0.059 
 GC+GG 47 (48.75%) 39 (31.71%) 0.58 (0.33-1.02)  
rs7903146 CC 58(49.57%) 63 (51.22%) 1 (reference) 0.99 
 CT+TT 59 (50.43%) 60 (48.78%) 1.00 (0.59-1.70)  
rs7901695 TT 36 (30.77%) 32 (26.02%) 1 (reference) 0.34 
 TC+CC 81 (69.23%) 91 (73.98%) 1.33 (0.74-2.40)  
rs7895340 AA 69 (58.97%) 82 (66.67%) 1 (reference) 0.069 
 GA+GG 48 (41.03%) 41 (33.33%) 0.59 (0.34-1.04)   
rs4506565 AA 35 (29.91%) 32 (26.02%) 1 (reference) 0.44 
  AT+TT 82 (70.09%) 91 (73.98%) 1.26 (0.70-2.28)   
HA (Gender=Female) 
SNPs 
Without T2D  
N (%) 
With T2D 
N (%) 
OR (95% CI) 
p* 
value 
rs12255372 GG 25 (42.37%) 39 (54.93%) 1 (reference) 0.20 
 GT+TT 34 (57.63%) 32 (45.07%) 0.63 (0.30-1.29)  
rs11196205 CC 36 (61.02%) 45 (63.38%) 1 (reference) 0.69 
 GC+GG 23 (38.98%) 26 (36.62) 0.86 (0.42-1.79)  
rs7903146 CC 27 (45.76%) 45 (63.38%) 1 (reference) 0.082 
 CT+TT 32 (54.24%) 26 (36.62%) 0.53 (0.26-1.09)  
rs7901695 TT 15 (25.42%) 22 (30.99%) 1 (reference) 0.56 
 TC+CC 44 (74.58%) 49 (69.01%) 0.78 (0.35-1.76)  
rs7895340 AA 36 (61.02%) 43 (60.56%) 1 (reference) 0.84 
 GA+GG 23 (38.98%) 28 (39.44%) 0.93 (0.45-1.9)  
rs4506565 AA 14 (23.73%) 22 (30.99%) 1 (reference) 0.41 
  AT+TT 45 (76.27%) 49 (69.01%) 0.71 (0.31-1.60)   
HA (Gender=Male) 
SNPs 
Without T2D  
N (%) 
With T2D n 
N (%) 
OR (95% CI) 
p* 
value 
rs12255372 GG 27 (47.37%) 29 (55.77%) 1 (reference) 0.80 
 GT+TT 30 (52.63%) 23 (44.23%) 0.90 (0.39- 2.08)  
rs11196205 CC 34 (58.62%) 39 (75.00%) 1 (reference) 0.034 
 GC+GG 24 (41.38%) 13 (25.00%) 0.35 (0.14-0.92)  
rs7903146 CC 31 (53.45%) 18 (34.62%) 1 (reference) 0.052 
 CT+TT 27 (46.55%) 34 (65.38%) 2.35 (0.99-5.56)  
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rs7901695 TT 21 (36.21%) 10 (19.23%) 1 (reference) 0.052 
 TC+CC 37 (63.79) 42 (80.77%) 2.62 (0.99-6.91)  
rs7895340 AA 33 (56.90%) 39 (75.00%) 1 (reference) 0.024 
 GA+GG 25 (43.10%) 13 (25.00%) 0.33 (0.12-0.86)  
rs4506565 AA 21 (36.21%) 10 (19.23%) 1 (reference) 0.052 
  AT+TT 37 (63.79) 42 (80.77%) 2.62 (0.99-6.91)   
*P value and odds ratios (OR) with 95% confidence interval (CI) were calculated using unconditional 
logistic models adjusted by BMI, gender, age, physical activity and calorie intake; HA= Haitian 
American. 
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Table 4. Comparison of T2D related metabolic traits between non-risk allele carriers and 
risk allele carriers of SNP rs12255372 in African Americans without T2D. 
Variables GG (N=56) GT+TT (N=64) p* value 
BMI (kg/m2) 29.09±1.22 31.5±1.23 0.036 
Waist circumference (cm) 98.52±1.15 102.18±1.15 0.16 
SBP (mm of Hg) 127.57±1.12 133.74±1.16 0.054 
DBP (mm of Hg) 83.81±1.14 89.57±1.15 0.010 
Triglycerides (mg/dl) 99.20±1.62 109.42±1.57 0.26 
Total cholesterol (mg/dl) 183.79±1.24 188.27±1.2 0.51 
HDL-C (mg/dl) 52.11±1.31 46.61±1.27 0.02 
LDL-C (mg/dl) 105.43±1.39 114.76±1.32 0.13 
FPG (mmol/L) 93.16±1.13 96.10±1.15 0.19 
A1C (%) 5.87±1.07 5.83±1.07 0.57 
Insulin 9.30±2.06 10.67±1.95 0.29 
HOMA2_B 105.00±1.65 106.84±1.45 0.83 
HOMA2_IR 77.97±1.9 70.2±1.92 0.39 
HOMA2_IS 1.28±1.9 1.43±1.92 0.38 
Number of MetS components 1.69±1.02 2.17±1.38 0.035 
Adiponectin 22.07±1.67 17.46±1.72 0.017 
Values are unadjusted mean ± SD for continuous variables or N for categorical variables. * Derived 
from t-test for means or chi-square test for percentage differences between cases and controls. BMI= 
body mass index; SBP= systolic blood pressure; DBP= diastolic blood; HDLC= high-density 
lipoprotein cholesterol; LDL-C=low density lipoprotein cholesterol;FPG= fasting plasma glucose; 
A1C= hemoglobin A1C; MetS= Metabolic Syndrome; PA_MET_wk= physical activity  measured by 
metabolic equivalents (MET) per week 
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Figure 1. Haploview plot showing linkage disequilibrium (LD) with r2 values and block structure 
for six selected SNPs of TCF7L2 gene for African American (1A) and Haitian American (1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1B: Haitian American 
1A: African American 
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CHAPTER V   STRENGTHS AND LIMITATIONS 
This study has several strengths. T2D is a heterogeneous disorder with contributions 
from peripheral insulin resistance and β-cell dysfunction. In the present study, in addition 
to the association analyses of TCF7L2 SNPs in relationship to the risk of T2D, we also 
investigated some T2D related biomarkers (FPG, A1C%) and quantitative intermediate 
phenotypes (e.g. HOMA2 indexes) in three high risk race/ethnic populations. We also 
investigated the differences within the Black race with regards to genetic influences on 
T2D as well as associated phenotypes. Findings from our study provided valuable 
information for the ethno-specific genetic association with T2D and related metabolic 
traits and suggested potential issues regarding population stratification within Blacks 
which need to be further validated. Additionally, besides genetic factors, environmental 
influences, such us dietary factors and gender effect were taken into consideration on the 
genetic association with the risk of T2D, which might shed some light on how genetic 
variants could modify specific metabolic processes to make an individual more 
susceptible (or less susceptible) to the harmful (or preventive) effects of environmental 
factors. The case-control candidate gene study has the advantage of looking closely at 
polymorphisms of one single gene and its association with the disease. This study could 
contribute in genotype determination of the candidate gene (TCF7L2) polymorphisms 
with some biological importance to T2D.  
This study has some limitations. Due to the relatively small sample size in each 
race/ethnic population, the genetic variants with modest effect on the T2D might be 
omitted. As the study focused on the genetic associations of only one gene (TCF7L2), the 
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influence of gene-gene interactions was not considered. The effects of polymorphisms on 
the regulation of TCF7L2 gene expression were not quantified, so direct relationship with 
the gene product could not be established. The participants in the study were self-reported 
ethnicities; resulting in possible genetic heterogeneity. Confounding due to population 
stratification can be controlled by ancestry-informative markers to avoid false 
associations could be used to address this problem. Nevertheless, both cases and controls 
of our studied population were selected from the same population pool and geographic 
area, with information on ethnicity up to two generations, which to some extend mitigate 
the heterogeneity effect. Additionally, due to the nature of case-control study, there might 
be a recall bias on dietary intake information.  
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CHAPTER VI   SUMMARY AND PROSPECTIVE 
Summary 
The correlations among TCF7L2 polymorphisms, type 2 diabetes and its related 
quantitative traits were examined in Cuban American, Haitian American and African 
American population of South Florida. Additionally, the genetic associations of TCF7L2 
polymorphisms with T2D were also explored for the effects of environmental influences 
such as gender and dietary factors.  
The main objective of this study was to examine the correlations of TCF7L2 gene 
polymorphisms with T2D in three ethnicities which are at high risk of T2D. For Cuban 
Americans, we were able to see associations between polymorphisms of this gene with 
the risk of T2D and some related quantitative traits. Due to few existing studies 
examining this association in Hispanic subgroup, of which majority were carried in 
populations of Mexican origin, replication is lacking in Cuban Americans, the third 
largest minority group in the United States. This research filled this knowledge gap and 
confirmed the implication of TCF7L2 in T2D development reported earlier in other 
race/ethnic populations [1-3]. The epidemic of T2D only dates 50 years. It is quite clear 
that during this period the environmental factors have changed dramatically. A traditional 
high energy-burning lifestyle has been replaced by a sedentary lifestyle and consumption 
of an energy-dense diet, a common phenomenon worldwide, especially pronounced in the 
United States [4]. Studies in Cuban Americans also suggested higher consumption of 
junk foods and low consumption in fruits and vegetables during the acculturation [5, 6]. 
Some investigators speculated that the genetic predisposition to T2D would work 
synergically with the environmental facilitators, especially poor dietary behavior, to 
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contribute to the development of T2D [7]. Thanks to the validated food frequency 
questionnaire used in the present study, we were able to perform further analysis on the 
interaction between TCF7L2 polymorphisms and some dietary factors on the risk of T2D 
in Cuban American [8]. Such gene-diet associations reported earlier by other studies were 
validated by our findings. Our study yielded new insights into the understanding of 
etiology of diabetes and have implications for prevention of T2D in individuals carrying 
TCF7L2 risk allele(s) through dietary modification. 
Inconsistent results often present in genetic association studies. This is particularly 
true for African Americans due to diverse heterogeneous subgroups within Blacks and 
further complicated by environmental factors [9, 10]. From our study, we were able to 
identify ethno-specific associations of TCF7L2 SNPs with the risk of T2D and metabolic 
traits in African Americans and Haitian Americans and suggested that the two ethnic 
groups may have different genetic risk factors under the complex interactions between 
genetic and environmental factors. Some recent investigation also suggested TCF7L2 
involved in adipogenesis and demonstrated risk associations with Metabolic Syndrome 
[11-14]. Consistent with these studies, we identified one SNP (rs12255372) in TCF7L2 
gene was correlated with BMI and some important metabolic traits in African American 
population. Additionally, gender effect on the genetic association that reported in 
previous genetic investigations was also found in our study. The gender differences in 
risk association of T2D could be ascribed to genetic effects and epigenetic mechanisms 
that further complicated by non-genetic factors such as environmental exposure, 
anatomical differences, and sex hormones [15]. 
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Minority populations that possess lineage from two or more genetic sources are 
usually at high risks for metabolic diseases such as T2D and cardiovascular diseases [16]. 
Understanding the similarities as well as differences among these ethnicities provided 
important public and clinical implications in T2D prevention and treatment. For the 
present research, we demonstrated entho-specific associations of TCF7L2 polymorphisms 
with the risk of T2D and T2D related quantitative traits in three underrepresented 
minority populations. Additionally, environmental modifications on such association 
provided new insights into the understanding of etiology of diabetes and have 
implications for nutrition intervention in individuals carrying TCF7L2 risk allele(s).  
Future study 
Due to the limited sample size, the present study may not have enough statistical 
power to detect the significant associations that were true to these three populations. 
Therefore, larger sample sizes will be optimal to observe credible and substantial effects 
of such genetic variants. The present study focused on association of polymorphisms of 
only one gene with T2D and did not look into adjoining genetic effects on the risk of 
T2D. Investigation with combined SNPs from multiple validated risk T2D candidate 
genes might provide a better evaluation and estimation for the overall risk of T2D. 
Recently, epigenetic study that investigated macro-/micro-nutrients and bioactive food 
elements constituting the nutritional environment that alters the genome, the epigenome, 
the posttranslational regulation and modification is emerging as an interesting field in 
Nutrition Science [17]. Results from our study as well as some previous investigations 
suggested modification effect of gene-diet interaction on the association of TCF7L2 
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polymorphisms and T2D. In vivo or in vitro functional follow up studies at molecular 
level are warranted to confirm these observed associations from cross-sectional studies. 
Once confirmed, further human clinical trials would be conducted for pursing 
individualized nutrition intervention. 
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